

TRANSMITTAL LETTER
(General - Patent Pending)Docket No.
15120

In Re Application Of: Joachim Hauber, et al.

APR 09 2002

Serial No.
10/025,367Filing Date
December 19, 2001Examiner
UnassignedGroup Art Unit
Unassigned

Title:


COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID
COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDSTO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Claim of Priority (herewith)
Certified Priority Document

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.



Signature

Dated: April 5, 2002

Peter I. Bernstein
Registration No. 43,497
SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530
(516) 742-4343I certify that this document and fee is being deposited
on April 5, 2002 with the U.S. Postal Service as
first class mail under 37 C.F.R. 1.8 and is addressed to the
Assistant Commissioner for Patents, Washington, D.C.
20231

Signature of Person Mailing Correspondence

Michelle Mustafa

Typed or Printed Name of Person Mailing Correspondence

PIB:dg

CC:



This Page Blank (uspto)



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Joachim Hauber, et al. **Examiner:** Unassigned
Serial No: 10/025,367 **Art Unit:** Unassigned
Filed: December 19, 2001 **Docket:** 15120
For: COMPOUNDS THAT AFFECT CD83 **Dated:** April 5, 2002
EXPRESSION, PHARMACEUTICAL
COMPOSITIONS COMPRISING SAID COMPOUNDS
AND METHODS FOR IDENTIFYING SAID COMPOUNDS


Assistant Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231

CLAIM OF PRIORITY

Sir:

Applicants in the above-identified application hereby claim the right of priority
in connection with Title 35 U.S.C. § 119 and in support thereof, herewith submit a certified
copy of German Patent Application No. 0031145.6, filed December 20, 2000.

Respectfully submitted,



Peter I. Bernstein
Registration No.: 43,497

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States
Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for
Patents, Washington, DC 20231 on April 5, 2002

Dated: April 5, 2002


Michelle Mustafa

This Page Blank (uspis)



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

CERTIFIED COPY OF PRIORITY DOCUMENT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

17.1.02

This Page Blank (uspto)

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

20 DEC 2000

1. Your reference

P13752 r2/sa

2. Patent application number

(The Patent Office will fill in this part)

0031145.6

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Viaxxel Biotech GmbH

Patents ADP number (if you know it)

Am Sandberg 10
D91088 Bubenreuth
Germany

If the applicant is a corporate body, give the country/state of its incorporation

Germany

4. Title of the invention

COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS

5. Name of your agent (if you have one)

David Lethem

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Hoffmann Eitle
European Patent Attorneys
Sardinia House
52 Lincoln's Inn Fields
London WC2A 3LZ

Patents ADP number (if you know it)

07156466001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

0

94 /

Claim(s)

5 /

Abstract

1 /

Drawing(s)

15+15 /

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

3 /

Request for preliminary examination and search (Patents Form 9/77)

1 /

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

12. Name and daytime telephone number of person to contact in the United Kingdom

David Lethem
Hoffmann Eitle

20/12/00

020 7404 0116

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Compounds that affect CD83 expression,
pharmaceutical compositions comprising said compounds and
methods for identifying said compounds

Background of the invention

The immune system of mammals must possess the capability to react to a very large number of foreign antigens. Lymphocytes constitute a central element of the immune system because they can recognize antigens and effect a specific, adaptive immune response. Lymphocytes can be divided into two general classes of cells, B lymphocytes which are capable of expressing antibodies and T lymphocytes that can be subdivided into CD4+ helper T cells and CD8+ cytotoxic T cells. Both of these sub-groups of T lymphocytes are capable of recognizing antigens associated with surface proteins known as the major histocompatibility complex (MHC). The recognition of the MHC occurs throughout the T cell receptor (TCR), a protein complex that is anchored in the cytoplasmic membrane of T cells. The CD8+ T cell receptor exclusively mediates interactions between MHC class I antigens and cytotoxic T cells; the CD4+ T cell receptor exclusively mediates interactions between MHC class II antigens and helper T cells.

The triggering of an immune response does not exclusively progress from T cells alone, but rather, through the interaction of T cells with so-called antigen presenting cells (APCs, also known as accessory cells) and their surface markers (for example MHC II).

These accessory cells can be sub-divided into "simple" APCs whose function is to present antigens and "professional" APCs that, aside from presenting antigens, also have an accessory function in stimulating lymphocytes. APCs themselves do not have antigen specificity but serve as "nature's adjuvant" by presenting antigens to T cells. Aside from mononuclear

phagocytes, dendritic cells (DC) are members of the APC type. In fact, DCs are the most potent APC known today and they are the only APC that are also able to stimulate naïve T cells.

As a result of their different characteristics and function, two types of dendritic cells have been classified to date: follicular dendritic cells (also known as lymphoid-related DCs) that are present in the lymph nodes, spleen and mucosa-associated lymph tissues and interdigitating dendritic cells (also known as myeloid-derived DCs) that are found in the interstitial space of most organs, in T cell rich zones of the lymph nodes and spleen and are distributed throughout the skin where they are known as Langerhans cells.

Immature dendritic cells, i.e. DCs that are not fully capable of stimulating T cells, have the function of taking up antigens and processing them into MHC-peptide complexes. Stimuli such as TNF-alpha (tumor necrosis factor) and CD40L induce the maturation of dendritic cells and lead to a massive de novo synthesis of MHC class I and MHC class II molecules and to a migration of the DC, for example, from the interstitial space of the internal organs through the blood into the lymph nodes of the spleen and liver. Moreover, increased expression of co-stimulator molecules (for example, CD80, CD86) and adhesion molecules (for example, LFA3) occurs during the migration phase into the secondary lymphoid tissues. Mature DC stimulate T lymphocytes upon arrival in the T cell rich regions of the secondary lymphoid tissue by presenting peptide antigens within the context of MHC class I or MHC class II to these T cells.

Depending on the conditions, DCs can stimulate the activation of a variety of T cells which, in turn, can bring about a differential response of the immune system. For example, as mentioned above, DCs that express MHC class I can cause cytotoxic T cells to proliferate and DCs that express MHC class II can interact with helper T cells. In the presence

of mature DCs and the IL-12 that they produce, these T cells mature into Th1 cells that produce interferon-gamma. Interferon-gamma and IL-12 serve together to promote the differentiation of T cells into killer cells. In the presence of IL-4, DCs induce T cells to differentiate into Th2 cells which secrete IL-5 and IL-4 that in turn activates eosinophils and assist B cells to produce antibodies (Banchereau, J. and Steinman, R.M. (1998) *Nature* 392: 245-252).

DCs can also induce a so-called mixed leukocyte reaction (MLR) in vitro, a model for allogenic T cell activation and graft rejection.

Mature DC characteristically express, amongst others (e.g. MHC I and II, CD80/86, CD40) the marker molecule CD83 on their cell surface (Zhou, L.-J. and Tedder, T.F. (1995) *J. Immunology*, vol. 154: 3821-3835). This is one of the best markers for mature DC known today.

CD83, a molecule from the Ig superfamily of proteins, is a single chain, 43 kDa glycoprotein consisting of 205 amino acids with a transmembrane domain and a 39 amino acid cytoplasmic domain and an Ig-like (V-type) extracellular domain that is expressed very strongly on the cell surface of mature DC. The extracellular domain of the CD83 protein differs from the typical Ig-like domain in that it is encoded by at least two exons: one exon only codes for a half of the Ig-like domain, whereas the other exon encodes the membrane spanning domain (see Zhou, L.-J., Schwarting, R., Smith, H.M. and Tedder, T.F. (1992) *J. Immunology*, vol. 149: 735-742).

The cDNA encoding CD83 contains a 618 bp open reading frame (see Genbank accession number Z11697 and Zhou, L.-J. et al, *supra* (1995)).

While the precise function of CD83 remains to be determined, it has been demonstrated that inhibition of CD83 cell surface expression on mature DC by interference with nuclear export of CD83 mRNA leads to a clear reduction in the capacity of these cells to stimulate T cells. (Kruse, M. et al. (2000) *J. Exp. Med.* 191: 1581-1589). Thus, CD83 appears to be required for DC function.

Therefore, pharmacological intervention with regard to CD83 expression may provide an opportunity to interfere with immune system functions involving, for example, the initiation of primary immune responses, autoimmune diseases, allergies and graft rejection.

The regulation of protein expression in a cell, i.e. the availability of mature mRNA to the translation machinery, is decisively influenced by various post-transcriptional RNA processing steps such as polyadenylation, capping, splicing, transport and localization within the cell and the control of mRNA stability. RNA-protein interactions play an essential role in the regulation of post-transcriptional gene expression.

One such protein is protein ELAV (Embryonic Lethal Abnormal Vision), a protein that was first characterized in the fruit fly *Drosophila melanogaster* and is essential for the development and maintenance of the nervous system. Deletion mutations in the ELAV gene frequently lead to lethal effects in *Drosophila* as a result of abnormal or missing nerve development (Antic, D. and Keene, J.D. (1997) *Am. J. Hum. Genet.* 61: 273-278; Keene, J.D., (1999) *PNAS (USA)* 96: 5-7)).

The *Drosophila* ELAV protein has been shown to belong to a superfamily of proteins, the so-called RRM (RNA recognition motif) superfamily, that has been highly conserved during evolution. Other members of this superfamily have been identified in human, rat, mouse, chicken and *Xenopus*, and

Zebrafish. This RRM superfamily encompasses four known human proteins (HuA = HuR (Ma, W.-J. et al. (1996) *J. Biol. Chem.* 271(14): 8144-8151), Genbank accession number U38175; HuB = Hel-N1 (King, P.H. et al. (1994) *J. Neurosci.* 14(4): 1943-1952), Genbank accession number U12431; HuC (as deposited by Manley, T. and Furneaux, H.M. under Genbank accession number L26405) and HuD (Szabo, A. et al. (1991) *Cell* 67(2): 325-333, Genbank accession number M62843). All Hu proteins typically contain three RNA binding domains (RRM 1-3) and a hinge region between RRM 2 and 3. The hinge region of HuR (= HuA) contains a shuttling sequence that is known as HNS (Hu nucleocytoplasmic shuttling) (Fan, X.C. and Steitz, J.A. (1998) *PNAS (USA)* 95:15293-15298). This sequence contains a signal for transport in the nucleus, a so-called NLS (nuclear localization signal) as well as a signal for nuclear export, a so-called NES (nuclear export signal).

While HuR has been shown to be ubiquitously expressed in all proliferating cells, HuB, HuC and HuD are expressed in a neuron-specific manner.

Although the exact function of these ELAV or ELAV-like proteins is not known, they are thought to be involved in the regulation of the transport, stability and translation of a group of early response gene (ERG) mRNAs such as those that code for proto-oncoproteins and cytokines. Thus, HuR has been implicated in regulating the transport, stability and translation of mRNAs such as GM-CSF, IL-2, c-myc, c-fos and GLUT1. This regulation has been demonstrated to occur via HuR binding to so-called ARE(s) (AU-rich elements) that are found within these mRNA molecules. AREs are sequence elements that often have the motif AUUUA typically within an AU-rich background, range in size from about 50 to 150 bases, and are present in the 3' non-translated regions of mRNA molecules where they are thought to act as destabilizing elements in the mRNA molecules in which they occur (see Chen, C.-Y. A. and Shyu, A.-B. (1995) *TIBS* 20: 465-470). For example, HuR

has been shown to bind to a core element of c-fos mRNA of 27 nucleotides that contain the AREs AUUUA, AUUUUA and AUUUUUA (Ma, W.-J. et al. (1996) J. Biol. Chem. 271(14): 8144-8151). It is thought that binding of HuR protein to the ARE(s) of a given mRNA molecule can protect the mRNA molecule from degradation by cellular enzymes.

An object of the present invention is to provide compounds that are capable of inhibiting CD83 expression and/or induction of the T cell stimulatory mode of DC and/or induction of so-called "regulatory cells".

A further object of the present invention is to provide pharmaceutical compositions comprising compounds that are capable of inhibiting CD83 expression and/or induction of the T cell stimulatory mode of DC and/or induction of so-called "regulatory cells".

A further object of the present invention is to provide an assay that is useful in screening and/or identifying compounds that are capable of inhibiting CD83 expression and/or induction of the T cell stimulatory mode of DC and/or induction of so-called "regulatory cells" and as such are useful as pharmaceutical agents.

Brief Description of the Drawings

Figure 1: Map of the pcDNA3-CD83 vector.

Figure 2: Map of the pcDNA3-ELAV (HuR) vector.

Figure 3: RNA gel mobility shift experiments with CD83 RNA (nucleotides 1 to 618 of SEQ ID NO:1); lane A: CD83 RNA; lane B: CD83 RNA + GST; lane C: CD83 RNA + GST-ELAV (HuR).

- Figure 4: RNA gel mobility shift experiments with CD83 RNA (nucleotides 1 to 618 of SEQ ID NO:1) and different proteins; lane A: CD83 RNA without added protein; lane B: CD83 RNA + GST-M9; lane C: CD83 RNA + GST-L5; lane D: CD83 RNA + GST-ELAV (HuR); lane E: CD83 RNA + GST.
- Figure 5: RNA gel competition mobility shift experiments with CD83 RNA (nucleotides 1 to 618 of SEQ ID NO:1) using increasing amounts of unlabeled CD83 RNA; lane A: labeled CD83 RNA without added unlabeled CD83 RNA; lanes B-G: labeled CD83 RNA with increasing amounts of unlabeled CD83 RNA.
- Figure 6: RNA gel mobility shift experiments with CD83 RNA (nucleotides 1 to 618 of SEQ ID NO:1) and sub-fragments with and without added ELAV (HuR) protein; lane A: CD83 RNA; lane B: CD83 RNA + GST-ELAV (HuR); lane C: CD83 RNA (nucleotides 1 to 294 of SEQ ID NO:1); lane D: CD83 RNA (nucleotides 1 to 294 of SEQ ID NO:1) + GST-ELAV (HuR); lane E: CD83 RNA (nucleotides 202 to 414 of SEQ ID NO:1); lane F: CD83 RNA (nucleotides 202 to 414 of SEQ ID NO:1) + GST-ELAV (HuR); lane G: CD83 RNA (nucleotides 295 to 618 of SEQ ID NO:1); lane H: CD83 RNA (nucleotides 295 to 618 of SEQ ID NO:1) + GST-ELAV (HuR).
- Figure 7: Secondary structure model of a DNA molecule from nucleotides 412 to 618 of SEQ ID NO:1 having an energy value of -41.8 kcal/mol as calculated at 37°C with the aid of the GCG program MFOLD.
- Figure 8: Secondary structure model of a DNA molecule from nucleotides 412 to 618 of SEQ ID NO:1 having an energy value of -41.7 kcal/mol as calculated at 37°C with the aid of the GCG program MFOLD.

- Figure 9: Secondary structure model of a DNA molecule from nucleotides 412 to 618 of SEQ ID NO:1 having an energy value of -40.8 kcal/mol as calculated at 37°C with the aid of the GCG program MFOLD.
- Figure 10: RNA gel mobility shift experiments with sub-fragments of CD83 RNA with and without added ELAV (HuR) protein; lane A: CD83 RNA (nucleotides 295 to 465 of SEQ ID NO:1); lane B: CD83 RNA (nucleotides 295 to 465 of SEQ ID NO:1) + GST-ELAV (HuR); lane C: CD83 RNA (nucleotides 466 to 618 of SEQ ID NO:1); lane D: CD83 RNA (nucleotides 466 to 618 of SEQ ID NO:1) + GST-ELAV (HuR).
- Figure 11: Cloning scheme for the reporter construct pBC12/CMV/CAT.
- Figure 12: CAT activity of the reporter construct pBC12/CMV/CAT without an insert containing CD83 coding sequences in comparison to the reporter construct pBC12/CMV/CAT with a CD83 insert containing nucleotides 412 to 615 of SEQ ID NO:1 as measured in a transient transfection assay using COS cells.
- Figure 13: CAT activity of the reporter construct pBC12/CMV/CAT with a CD83 insert containing nucleotides 412 to 615 of SEQ ID NO:1 as measured in a transient transfection assay using COS cells that were or were not co-transfected with pcDNA-ELAV (HuR).
- Figure 14: CAT activity of the reporter construct pBC12/CMV/CAT with a CD83 insert containing nucleotides 412 to 615 of SEQ ID NO:1 in the

sense or antisense orientation as measured in a transient transfection assay using COS cells that were or were not co-transfected with pCDNA-ELAV (HuR) and express ELAV (HuR).

Figure 15: CAT activity of the reporter construct pBC12/CMV/CAT with a CD83 insert containing nucleotides 412 to 615 of SEQ ID NO:1, nucleotides 412 to 465 of SEQ ID NO:1 or nucleotides 466 to 615 of SEQ ID NO:1 as measured in a transient transfection assay using COS cells that were or were not co-transfected with pCDNA-ELAV (HuR).

Figure 16: Secondary structure model of a DNA molecule from nucleotides 466 to 615 of SEQ ID NO:1 having an energy value of -29.7 kcal/mol as calculated at 37°C with the aid of the GCG program MFOLD.

Figure 17: Secondary structure model of a DNA molecule from nucleotides 466 to 615 of SEQ ID NO:1 having an energy value of -28.4 kcal/mol as calculated at 37°C with the aid of the program GCG program MFOLD.

Summary of the invention

It has been surprisingly found that HuR has the ability to specifically bind to mRNA molecules encoding the mature DC marker protein CD83. Moreover, it was unexpectedly found that this specific binding of HuR to CD83 mRNA occurs as a result of the interaction between HuR and a cis-active element comprising a portion of the coding region of the CD83 mRNA molecule and that this interaction leads to the increased expression of mRNA molecules comprising this portion of the CD83 mRNA.

Therefore, compounds that are capable of specifically blocking the interaction between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins will prevent correct intracellular transport and/or stabilization of said mRNA which, in turn, will lead to decreased expression of the protein encoded by said mRNAs.

The present invention provides such compounds.

Thus, the present invention relates to compounds that specifically block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell.

The nucleic acid sequence encoding human CD83 protein as well as the amino acid sequence of CD83 are described in Zhou, L.J. et al. (1992) J. Immunol. 149(2): 735-742 (Genbank accession number Z11697) and are provided in SEQ ID NO:1 and SEQ ID NO:2 respectively.

As defined herein, a member of the CD83 family of proteins includes any naturally occurring protein that has at least 70%, preferably 80%, and more preferably 90% or more amino acid identity to the human CD83 as depicted in SEQ ID NO:2, resulting in specific binding of ELAV proteins to the CD83 cis-active RNA sequence of this protein.

Thus, aside from CD83 itself, members of the CD83 family of proteins include the mouse HB15 protein that is encoded by the nucleic acid sequence of SEQ ID NO:3 and is represented by the amino acid sequence provided in SEQ ID NO:4, (Genbank accession number NM_009856 (Berchthold et al)).

A preferable member of the CD83 family of proteins for the purpose of the invention is the CD83 protein as shown in SEQ ID NO:2.

The nucleic acid sequence encoding HuR protein as well as the amino acid sequence of HuR are described in Ma, W.-J. et al. (1996) J. Biol. Chem. 271(14): 8144-8151 (GenBank accession number U38175) and are provided in SEQ ID NO:5 and SEQ ID NO:6 respectively.

As defined herein, a member of the HuR family of proteins includes any naturally occurring protein that has 90% or more amino acid identity to HuR. Thus, aside from HuR itself, members of the HuR family of proteins include the proteins encoded by the elrA gene of *Xenopus* (Good, P.J. (1995) PNAS (USA) 92(10): 4557-4561; Genbank accession number U17596; the mouse melG protein (Atasoy, U. et al. (1998) J. Cell Science 111: 3145-3156; GenBank accession number U65735)), chicken HuA protein (Wakamatsu, Y. and Weston, J.A. (1997) Development 124(17): 3449-3460; GenBank accession number AF176673); zebrafish HuA protein (Genbank accession number AF184244) and HuG protein (Genbank accession number AF184245).

A preferable member of the HuR family of proteins for the purpose of the invention is the HuR protein as shown in SEQ ID NO:6.

As defined herein, the term "specifically block" is used to indicate that the compounds of the present invention are capable of disrupting the interaction between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins at physiological pH and salt concentrations, preferably, at pH concentrations ranging from pH 6.0 to 8.0 and/or at salt concentrations ranging from 50 mM to 250 mM, preferably 125 mM to 175 mM.

A preferred assay for measuring the expression of a member of the CD83 family of proteins in a cell is provided in the examples. Other useful assays for this purpose include

fluorescence/ indirect immunofluorescence assays, Western analysis, ELISA analysis, immunoprecipitation assays, other assays based on the expression of a reporter gene, such as chloramphenicol acetyltransferase (CAT), luciferase, beta-galactosidase and GFP/BFP, FACS analysis, direct protein gel analysis with staining of the gel and coupled in vitro transcription/translation assays.

A preferred assay for determining the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins is provided in the examples. Other useful assays for this purpose include filter binding assays, Biacore interaction analysis (Biacore, Uppsala, Sweden), Scintillation Proximity Assay (Amersham Pharmacia Biotech, Freiburg, Germany), RNase protection assays, cell-based RNA binding assays (see Blair et al. (1998) RNA 4: 215-225), yeast 3-hybrid assays (for example, RNA-Protein Hybrid Hunter [®] System (Invitrogen, Groningen, The Netherlands), and reporter gene assays in eukaryotic cells as described above.

The compounds of the present invention cause a disruption in the interaction between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins that can be reversible or irreversible and preferably correspond to an inhibition of the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins of at least 25%, more preferably at least 50%, still more preferably at least 75% and most preferably at least 90% or greater as measured in one or more of the above assays.

In one embodiment, compounds of the invention comprise nucleic acid molecules that specifically block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that

reduce expression of a member of the CD83 family of proteins in a cell.

The nucleic acids of the present invention can be in the form of DNA (deoxyribonucleic acid) which contains the bases adenine, thymine, guanine and cytosine or RNA (ribonucleic acid) which contains the bases adenine, uracil, guanine and cytosine or mixtures of the two.

Preferably, these compounds comprise a nucleic acid molecule that contains at least a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof.

When the nucleic acid molecule of the invention is derived from a portion of the coding region of human CD83 protein, the portion of the coding region is preferably from nucleotide 466 to 618 of the sequence in SEQ ID NO:1 or a derivative thereof. Alternatively, the portion of the coding region is from nucleotide 466 to 615 of the sequence in SEQ ID NO:1.

When the nucleic acid molecule of the invention is derived from a portion of the coding region of the mouse HB15 protein, the portion of the coding region is preferably from about nucleotide 14 to 604 of the sequence in SEQ ID NO:3. Alternatively, the portion of the coding region is from nucleotide 14 to 601 of the sequence in SEQ ID NO:3.

Other naturally occurring nucleic acids that can be used for the present invention can be obtained by hybridizing a nucleic acid comprising, for example, all or a portion of the human CD83 coding region or mouse HB15 coding region to various sources of nucleic acids (genomic DNA, cDNA, RNA) from other animals, preferably mammals, or from other tissues of the same organism.

Hybridization refers to the binding between complementary nucleic acid sequences (e.g., sense/antisense). As is known to those skilled in the art, the T_m (melting temperature) refers to the temperature at which the binding between sequences is no longer stable. As used herein, the term "selective hybridization" refers to hybridization under moderately stringent or highly stringent conditions, which can distinguish CD83 related nucleotide sequences from unrelated sequences.

In nucleic acid hybridization reactions, the conditions used in order to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of sequence complementarity, sequence composition (e.g., the GC v. AT content), and type (e.g., RNA v. DNA) of the hybridizing regions can be considered in selecting particular hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

In general, the stability of a nucleic acid hybrid decreases as the sodium ion decreases and the temperature of the hybridization reaction increases. An example of moderate stringency hybridization reaction is as follows: 2 x SSC/0.1% SDS at about 37°C or 42°C (hybridization conditions); 0.5 x SSC/0.1% SDS at about room temperature (low stringency wash conditions); 0.5 x SSC/0.1 % SDS at about 42 ° C (moderate stringency wash conditions). An example of high stringency hybridization conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.5 x SSC/0.1% SDS at about room temperature (low stringency wash conditions); 0.5 x SSC/0.1% SDS at about 42°C (moderate stringency wash conditions); and 0.1 x SSC/0.1% SDS at about 65°C (high stringency conditions).

Typically, the wash conditions are adjusted so as to attain the desired degree of stringency. Thus, hybridization stringency can be determined, for example, by washing at a particular condition, e.g., at low stringency conditions or high stringency conditions, or by using each of the conditions, e.g., for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. Optimal conditions for selective hybridization will vary depending on the particular hybridization reaction involved, and can be determined empirically.

The compounds of the present invention also include derivatives of each of the nucleic acid molecules according to the invention as mentioned above in which one or more nucleotides has been added, deleted, substituted, inserted or inverted but still specifically block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell.

The nucleic acids of the invention can have a secondary structure corresponding to that shown in Figure 16 comprising a 3-pronged stem-loop structure or Figure 17 or a similar secondary structure having an energy of -28.4 kcal/mol or less, preferably -29.7 kcal/mol or less when analyzed according to the MFOLD program available from the University of Wisconsin, USA at (<http://www.qcqc.com>) using a folding temperature of 37°C, a maximum size of interior loop of 30 and maximum loopsidiness of an interior loop of 30 and nucleotide sequence in the form of a DNA molecule having nucleotides that correspond to the nucleotide sequence from 466 to 615 of SEQ ID NO:1.

The nucleic acids of the invention can also have a secondary structure corresponding to that shown in Figures 7 to 9 comprising a 3-pronged stem-loop structure or a similar

secondary structure having an energy of -40.8 kcal/mol or less, preferably -41.7 kcal/mol or less and more preferably -41.8 kcal/mol when analyzed according to the MFOLD program available from the University of Wisconsin, USA at (<http://www.gcq.com>) using a folding temperature of 37°C, a maximum size of interior loop of 30 and maximum loopsiderness of an interior loop of 30 and nucleotide sequence in the form of a DNA molecule having nucleotides that correspond to the nucleotide sequence from 412 to 618 of SEQ ID NO:1.

Other nucleic acid molecules with a secondary structure according to the invention are obtainable by selecting two nucleotides in a naturally occurring RNA or DNA molecule encoding a member of the CD83 family of proteins, for example the CD83 nucleic acid sequence, that are base paired in a manner shown in Figures 7 to 9, 16 or 17 and then substituting these nucleotides in a pair-wise fashion such that the substitute nucleotides are based paired. Thus, in RNA molecules of the invention, a paired C-G nucleotide can be substituted by a G-C pair, an A-U pair or a U-A pair, a G-C base pair can be substituted by a C-G pair, an A-U pair or a U-A pair, an A-U base pair can be substituted by a U-A pair, a C-G pair or a G-C pair, and a U-A base pair can be substituted by a A-U pair, a C-G pair or a G-C pair. Likewise, in DNA molecules of the invention, a paired C-G nucleotide can be substituted by a G-C pair, an A-T pair or a T-A pair, a G-C base pair can be substituted by a C-G pair, an A-T pair or a T-A pair, an A-T base pair can be substituted by a T-A pair, a C-G pair or a G-C pair, and a T-A base pair can be substituted by a A-T pair, a C-G pair or a G-C pair. Preferably, C-G base pairs are substituted with G-C base pairs, A-T or A-U base pairs with T-A or U-A base pairs, respectively.

The nucleic acid molecules of the present invention can also be modified throughout their length and/or at the 5' and/or 3' end(s) to increase their stability.

Such modifications can be obtained by using α -anomers or 2'-O-alkyl ribosides (G. Zon, (1988) *Pharmaceutical Research* 5(9): 539-549; Helene, C. and Toulme, J.-J. (1990) *Biochem. Biophys. Acta* 1049: 99-125; Stein, C.A. and Cohen, J.S. (1988) *Cancer Research* 48:2659-2668). In addition, the phosphate backbone of the nucleic acid can be modified according to procedures known in the art to create nucleic acids of the invention comprising phosphothioate analogues, in which a non-bridging atom of the phosphate group is replaced by a sulfur atom, analogues in which a non-bridging atom of the phosphate group is replaced by a selenium atom, phosphorodithioate analogues, in which both non-bridging groups of the phosphate atom are replaced by sulfur, methylphosphonates, in which a non-bridging atom of the phosphate group is replaced by a methyl group, phosphoramidates, in which a non-bridging atom of the phosphate group is replaced by amide group substituted with one or two alkyl methyl or ethyl groups, and phosphotriesters, in which a non-bridging atom of the phosphate group is replaced by a methyl or ethyl ester. Further stabilizing modifications are described in Freier, S.M. and Altmann, K.-H., (1997) *NAR* 25(22): 4429-4443.

Furthermore, modifications to the nucleic acids of the invention include the addition of heterologous terminal sequences that form a terminal step-loop structure and therefore increase the stability of the cis-active sequence of the invention.

Furthermore, one or more of the bases of the nucleic acids can be replaced by modified bases. These modified bases include 2-methyladenine, 1-methylguanine, 5-methylcytosine, and 5-hydroxymethylcytosine.

The nucleic acids of the invention may also comprise non-nucleic acid components such as proteins that can be attached

to the nucleic acids via a large number of known bifunctional linkers known in the art (for example, maleimidohexanoyl-N-hydroxysuccinimide ester and other linkers as described on pages 173 to 214 of the Pierce Products catalogue 1999/2000) and can aid in the cellular uptake of the nucleic acids. Examples for this are the tat-derived polypeptides as described by Vives, E. et al. (1997) J. Biol. Chem. 272(25): 16010-16017 and Bhorade, R. et al. (2000) Bioconjugate Chemistry 11(3): 301-305 and penetratin as described by Fischer, P.M. et al (2000) J. Pept. Res. 55(2): 163-172 and Bolton, S.J. et al. (2000) Eur. J. Neurosci. 12(8): 2847-2855.

Preferably, the above mentioned nucleic acids of the present invention are such that they do not contain regulatory sequences that lead to the expression of a polypeptide or protein from said nucleic acid in a cell.

In a further embodiment, compounds of the invention include protein molecules that specifically block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell.

Thus, compounds of the invention comprise derivatives of members of the ELAV superfamily of proteins that specifically block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell.

As defined herein, "members of the ELAV superfamily of proteins" include proteins comprising a partial amino acid sequence of ELAV (Robinow, S. et al. (1988) Science 242: 1570-1572, Genbank accession number M21152), (HuA = HuR (Ma, W.-J. et al. (1996) J. Biol. Chem. 271(14): 8144-8151),

Genbank accession number U38175; HuB = Hel-N1 (King, P.H. et al. (1994) J. Neurosci. 14(4): 1943-1952, Genbank accession number U12431, SEQ ID NO:22 and 23); HuC (as deposited by Manley, T. and Furneaux, H.M. under Genbank accession number L26405, SEQ ID NO:24 and 25) and HuD (Szabo, A. et al. (1991) Cell 67(2): 325-333, Genbank accession number M62843, SEQ ID NO:26 and 27) as well as naturally occurring proteins encoded by the ELAV, HuA (=HuR), HuB (= Hel-N1), HuC and HuD genes that result from alternative gene expression, for example from alternate RNA splicing, such as HuDpro, HuDmex, Hel-N2 and HuC isoforms (See Liu, J. et al. (1995) Neurology 45:544-550 and Goa, F.C. (1994) PNAS (USA) 91:11207-11211). Furthermore, "members of the ELAV superfamily of proteins" include naturally occurring animal, for example zebrafish (Genbank accession numbers AF184245, AF184244, U62018, U17602, U17601 and U17600) preferably, mammal, protein homologues of the above proteins. For example, the Rel-N1 and Rel-N2 protein of rat (King, P.H. (1994) Gene 151(1-2): 261-265), rat "HuD" (protein sequence accession number O09032), rat ELAV-type RNA binding protein 3 (protein sequence accession number NP_058893), mouse Mel-N1 (Genbank accession number NM_010486), mouse "HuR" (Genbank accession number NM_010485), mouse "HuD" (Genbank accession number NM_010488) are encompassed within this definition.

Derivatives of a member of the ELAV superfamily of proteins according to the invention include members of the ELAV superfamily of proteins as defined above in which one or more amino acids has been added, deleted, substituted, inserted or inverted but that are still capable of specifically blocking the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell.

When one or more amino acids of a member of the ELAV superfamily of proteins is substituted to arrive at a

derivative of a member of the ELAV superfamily of proteins, it is preferred that the one or more amino acids are conservatively substituted. For example, conservative substitutions include substitutions in which aliphatic amino acid residues such as Met, Ile, Val, Leu or Ala are substituted for one other. Likewise, polar amino acid residues can be substituted for each other such as Lys and Arg, Glu and Asp or Gln and Asn.

According to the invention, derivatives of a member of the ELAV superfamily of proteins also include derivatives in which one or more of the amino acids therein has an altered side chain. Such derivatized polypeptides include, for example, those comprising amino acids in which free amino groups form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups; the free carboxy groups form salts, methyl and ethyl esters; free hydroxyl groups that form O-acyl or O-alkyl derivatives as well as naturally occurring amino acid derivatives, for example, 4-hydroxyproline, for proline, 5-hydroxylysine for lysine, homoserine for serine, ornithine for lysine etc. Also included are amino acid derivatives that can alter covalent bonding, for example, the disulfide linkage that forms between two cysteine residues that produces a cyclized polypeptide.

The length of the derivatives of a member of the ELAV superfamily of proteins according to the invention can vary as long as said derivative specifically blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and reduces expression of a member of the CD83 family of proteins in a cell. Preferably, the derivatives of a member of the ELAV superfamily of proteins according to the invention are less than 250, more preferably 200 and most preferably 150 or less amino acids in length.

Preferably, a derivative of a member of the ELAV superfamily of proteins according to the invention does not contain a complete set of RRM1, RRM2 and RRM3 or the hinge region, including HNS.

For HuR, a complete RRM1 region is defined as the RNA Recognition Region from amino acid 19 to 100 of SEQ ID NO:6. For HuR, a complete RRM2 region is defined as the RNA Recognition Region from amino acid 103 to 189 of SEQ ID NO:6. For HuR, a complete RRM3 region is defined as the RNA Recognition Region from amino acid 245 to 326 of SEQ ID NO:6. Corresponding RRM1, RRM2 and RRM3 and hinge or HNS regions for other ELAV-like proteins can be deduced based on their homologies to the RRM1, RRM2 and RRM3 regions of HuR as defined above and preferably have 70%, more preferably, 80, and most preferably at least 90 % homology to amino acids 19 to 100 of SEQ ID NO:6 for RRM1, amino acids 103 to 189 of SEQ ID NO:6 for RRM2, amino acids 245 to 326 of SEQ ID NO:6 for RRM3 and amino acids 190 to 244 of SEQ ID NO:6 for the hinge region, including amino acids 205 to 237 of SEQ ID NO:6 for HNS.

In a further embodiment, compounds of the invention comprise derivatives of protein ligands to HuR that specifically block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell.

As defined herein, "protein ligands to HuR" include proteins comprising a partial amino acid sequence of SET α (Protein sequence accession number I59377), SET β (Protein sequence accession number A45018), pp32 (Genbank accession number U73477) and APRIL (Genbank accession number Y07969) as well as naturally occurring animal, preferably mammal, homologues of these proteins.

Derivatives of protein ligands to HuR according to the invention include SET α , SET β , pp32 and APRIL proteins as defined above in which one or more amino acids has been added, deleted, substituted, inserted or inverted but that are still capable of specifically blocking the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell.

When one or more amino acids of a protein ligand to HuR is substituted to arrive at a derivative of a member of the ELAV superfamily of proteins, it is preferred that the one or more amino acids are conservatively substituted. For example, conservative substitutions include substitutions in which aliphatic amino acid residues such as Met, Ile, Val, Leu or Ala are substituted for one other. Likewise, polar amino acid residues can be substituted for each other such as Lys and Arg, Glu and Asp or Gln and Asn.

According to the invention, protein ligands to HuR also include such proteins in which one or more of the amino acids therein has an altered side chain. Such derivatized proteins include, for example, those comprising amino acids in which free amino groups form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups; the free carboxy groups form salts, methyl and ethyl esters; free hydroxyl groups that form O-acyl or O-alkyl derivatives as well as naturally occurring amino acid derivatives, for example, 4-hydroxyproline, for proline, 5-hydroxylysine for lysine, homoserine for serine, omithine for lysine etc. Also included are amino acid derivatives that can alter covalent bonding, for example, the disulfide linkage that forms between two cysteine residues that produces a cyclized polypeptide.

The proteins according to the invention can be obtained using standard techniques for protein purification, for example, by

chromatography (e.g., ion-exchange, size-exclusion, reverse-phase, immunoaffinity etc.). Other protein purification methods known in the art additionally can be used (see e.g., Deutscher et al., Guide to Protein Purification: Methods in Enzymology, Vol. 182, Academic Press, 1990). Alternatively, the proteins according to the invention can be obtained using recombinant expression methods as disclosed herein. For example, polynucleotide encoding the protein can be produced, inserted into a vector and transformed into host cells using well known techniques described herein and further known in the art (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989). Following transformation, protein may be isolated and purified in accordance with conventional methods. For example, lysate prepared from an expression host (e.g., bacteria) can be purified using HPLC, size-exclusion chromatography, gel electrophoresis, affinity chromatography, or other purification technique. Substantially pure proteins can also be obtained by chemical synthesis using a peptide synthesizer (e.g., Applied Biosystems, Inc., Foster City, CA; Model 430A or the like).

The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention.

In addition, the present invention relates to the use of these pharmaceutical compositions for regulating an immune response involving the direct or indirect participation of DC. Preferably, the pharmaceutical compositions of the present invention are capable of reducing the expression of CD83 or a member of the CD83 family of proteins.

Moreover, the present invention relates to the use of the compounds of the present invention for the production of a pharmaceutical composition or medicament for regulating an

immune response involving the direct or indirect participation of DC.

Furthermore, the invention relates to a method of treatment or prevention of disorders, diseases and syndromes involving the direct or indirect participation of DC by regulating an immune response, wherein an effective amount of a compound according to the invention or a pharmaceutical composition according to the invention comprising said compound is administered to a subject.

Thus, the compounds of the present invention can be used to inhibit CD83 protein expression and/or induction of the T cell stimulating mode of DC or induction of so-called "regulatory" T cells and thereby treat or prevent a variety of disorders, diseases and syndromes. "Regulatory" T cells are defined as IL-10-producing non-proliferating CD25⁺ T cells.

For example, the compounds of the present invention can be used to modulate the growth, differentiation and/or activation of a variety of T cells such as cytotoxic T cells and helper T cells, the differentiation of helper T cells into Th1 cells or Th2 cells, the growth, stimulation and/or differentiation of B cells and treat or prevent disorders, diseases and syndromes caused by the failure of the body to regulate these processes in a healthy manner.

In addition, the compounds of the present invention can be used to treat or prevent rejection of tissue and/or organ transplants, particularly xenogenic tissue and/or organ transplants, that occurs as a result of for example graft-vs.-host disease or host-vs.-graft disease.

In a further embodiment of the present invention, the compounds of the present invention can be used to treat or

prevent undesirable response to foreign antigens and therewith allergies and asthma or similar conditions.

Other disorders, diseases and syndromes that can be treated or prevented by the compounds of the present invention include autoimmune syndromes such as myasthenia gravis, multiple sclerosis and systemic lupus erythematosus, skin diseases such as psoriasis, rheumatoid arthritis and AIDS.

For therapeutic or prophylactic use, the compounds of the present invention are administered to a subject, preferably a mammal, more preferably a human patient, for treatment or prevention in a manner appropriate for the medical indication.

The production of pharmaceutical compositions with an amount of one or more compounds according to the invention and/or their use in the application according to the invention occurs in the customary manner by means of common pharmaceutical technology methods. For this, the compounds according to the invention are processed together with suitable, pharmaceutically acceptable adjuvants and/or carriers to medicinal forms suitable for the various indications and types of application. Thereby, the medicaments can be produced in such a manner that the respective desired release rate is obtained, for example a quick flooding and/or a sustained or depot effect.

Preparations for parenteral use, to which injections and infusions belong, are among the most important systemically employed medicaments for the above mentioned indications.

Preferably, injections are prepared either in the form of vials or also as so-called ready-to-use injection preparations, for example as ready-to-use syringes or single use syringes in addition to perforation bottles for multiple withdrawals. Administration of the injection preparations can

occur in the form of subcutaneous (s.c.), intramuscular (i.m.), intravenous (i.v.), internodal (i.n.) or intracutaneous (i.c.) application. The respective suitable injection forms can especially be produced as solutions, crystal suspensions, nanoparticulate or colloid-disperse systems, such as for example, hydrosols.

The injectable formulations can also be produced as concentrates which can be adjusted with aqueous isotonic dilution agents to the desired dosage of the compounds of the invention. Furthermore, they can also be produced as powders, such as for example lyophilisates, which are then preferably dissolved or dispersed immediately before application with suitable diluents. The infusions can also be formulated in the form of isotonic solutions, fat emulsions, liposome formulations, microemulsions and liquids based on mixed micells, for example, based on phospholipids. As with injection preparations, infusion formulations can also be prepared in the form of concentrates to dilute. The injectable formulations can also be applied in the form of continuous infusions as in stationary as well as in out-patient therapy, for example in the form of mini-pumps.

Albumin, plasma expanders, surface active compounds, organic solvents, pH influencing compounds, complex forming compounds or polymeric compounds can be added to the parenteral medicinal forms with the aim of decreasing the adsorption of the compounds of the present invention to materials such as injection instruments or packaging materials, for example plastic or glass.

The compounds according to the invention can be bound to nanoparticles in the preparations for parenteral use, for example on finely dispersed particles based on poly(meth)acrylates, polyacetates, polyglycolates, polyamino acids or polyether urethanes. The parenteral formulations can also be constructively modified as depot preparations, for

example on the multiple unit principle, where the compounds of the present invention are incorporated in a most finely distributed and/or dispersed, suspended form or as crystal suspensions, or on the single unit principle, where the compounds according to the invention are enclosed in a medicinal form, for example, a tablet or a seed which is subsequently implanted. Often, these implantation or depot medicaments in single unit and multiple unit medicinal forms consist of so-called biodegradable polymers, such as for example, polyether urethanes of lactic and glycolic acid, polyether urethanes, polyamino acids, poly(meth)acrylates or polysaccharides.

Sterilized water, pH value influencing substances, such as for example organic and inorganic acids or bases as well as their salts, buffer substances for setting the pH value, agents for isotonicity, such as for example sodium chloride, monosodium carbonate, glucose and fructose, tensides and/or surface active substances and emulsifiers, such as for example, partial fatty acid esters of polyoxyethylene sorbitan (Tween®) or for example fatty acid esters of polyoxethylene (Cremophor®), fatty oils such as for example peanut oil, soybean oil and castor oil, synthetic fatty acid esters, such as for example ethyl oleate, isopropyl myristate and neutral oil (Miglyol®) as well as polymer adjuvants such as for example gelatin, dextran, polyvinylpyrrolidone, organic solvent additives which increase solubility, such as for example propylene glycol, ethanol, N,N-dimethylacetamide, propylene glycol or complex forming compounds such as for example citrates and urea, preservatives, such as for example hydroxypropyl benzoate and hydroxymethyl benzoate, benzyl alcohol, anti-oxidants, such as for example sodium sulfite and stabilizers, such as for example EDTA, are suitable as adjuvants and carriers in the production of preparations for parenteral use.

In suspensions, addition of thickening agents to prevent the settling of the compounds of the present invention from tensides and peptizers, to secure the ability of the sediment to be shaken, or complex formers, such as EDTA, ensues. This can also be achieved with the various polymeric agent complexes, for example with polyethylene glycols, polystyrol, carboxymethylcellulose, Pluronic® or polyethylene glycol sorbitan fatty acid esters. The compounds according to the invention can also be incorporated in liquid formulations in the form of inclusion compounds, for example with cyclodextrins. As further adjuvants, dispersion agents are also suitable. For production of lyophilisates, builders are also used, such as for example mannite, dextran, saccharose, human albumin, lactose, PVP or gelatin varieties.

A further systemic application form of importance is peroral administration as tablets, hard or soft gelatin capsules, coated tablets, powders, pellets, microcapsules, oblong compressives, granules, chewable tablets, lozenges, gums or sachets. These solid peroral administration forms can also be prepared as sustained action and/or depot systems. Among these are medicaments with an amount of one or more micronized compounds of the present invention, diffusions and erosion forms based on matrices, for example by using fats, wax-like and/or polymeric compounds, or so-called reservoir systems. As a retarding agent and/or agent for controlled release, film or matrix forming substances, such as for example ethylcellulose, hydroxypropylmethylcellulose, poly(meth)acrylate derivatives (for example Eudragit®), hydroxypropylmethylcellulose phthalate are suitable in organic solutions as well as in the form of aqueous dispersions. In this connection, so-called bio-adhesive preparations are also to be named in which the increased retention time in the body is achieved by intensive contact with the mucus membranes of the body. An example of a bio-adhesive polymer is the group of Carbomers®.

For sublingual application, compressives, such as for example non-disintegrating tablets in oblong form of a suitable size with a slow release of the compounds of the present invention, are especially suitable. For purposes of a targeted release of compounds of the present invention in the various sections of the gastrointestinal tract, mixtures of pellets which release at the various places are employable, for example mixtures of gastric fluid soluble and small intestine soluble and/or gastric fluid resistant and large intestine soluble pellets. The same goal of releasing at various sections of the gastrointestinal tract can also be conceived by suitably produced laminated tablets with a core, whereby the coating of the agent is quickly released in gastric fluid and the core of the agent is slowly released in the small intestine milieu. The goal of controlled release at various sections of the gastrointestinal tract can also be attained by multilayer tablets. The pellet mixtures with differentially released agent can be filled into hard gelatin capsules.

Anti-stick and lubricant and separating agents, dispersion agents such as flame dispersed silicone dioxide, disintegrants, such as various starch types, PVC, cellulose esters as granulating or retarding agents, such as for example wax-like and/or polymeric compounds on the basis of Eudragit®, cellulose or Cremophor® are used as a further adjuvants for the production of compressives, such as for example tablets or hard and soft gelatin capsules as well as coated tablets and granulates.

Anti-oxidants, sweetening agents, such as for example saccharose, xylite or mannite, masking flavors, aromatics, preservatives, colorants, buffer substances, direct tableting agents, such as for example microcrystalline cellulose, starch and starch hydrolysates (for example Celutab®), lactose, polyethylene glycols, polyvinylpyrrolidone and dicalcium phosphate, lubricants, fillers, such as lactose or

starch, binding agents in the form of lactose, starch varieties, such as for example wheat or corn and/or rice starch, cellulose derivatives, for example methylcellulose, hydroxypropylcellulose or silica, talcum powder, stearates, such as for example magnesium stearate, aluminum stearate, calcium stearate, talc, siliconized talc, stearic acid, acetyl alcohol and hydrated fats are used.

In this connection, oral therapeutic systems constructed especially on osmotic principles, such as for example GIT (gastrointestinal therapeutic system) or OROS (oral osmotic system), are also to be mentioned.

Effervescent tablets or tabs, both of which represent immediately drinkable instant medicinal forms which are quickly dissolved or suspended in water are among the perorally administratable compressives. Among the perorally administratable forms are also solutions, for example drops, juices and suspensions, which can be produced according to the above given method, and can still contain preservatives for increasing stability and optionally aromatics for reasons of easier intake, and colorants for better differentiation as well as antioxidants and/or vitamins and sweeteners such as sugar or artificial sweetening agents. This is also true for inspisated juices which are formulated with water before ingestion. Ion exchange resins in combination with one or more compounds of the present invention are also to be mentioned for the production of liquid ingestable forms.

A special release form consists in the preparation of so-called floating medicinal forms, for example based on tablets or pellets which develop gas after contact with body fluids and therefore float on the surface of the gastric fluid. Furthermore, so-called electronically controlled release systems can also be formulated by which release of the compounds of the present invention can be selectively adjusted to individual needs.

A further group of systemic administration and also optionally topically effective medicinal forms are represented by rectally applicable medicaments. Among these are suppositories and enema formulations. The enema formulations can be prepared based on tablets with aqueous solvents for producing this administration form. Rectal capsules can also be made available based on gelatin or other carriers.

Hardened fat, such as for example Witepsol®, Massa Estarinum®, Novata®, coconut fat, glycerol-gelatin masses, glycerol-soap-gels and polyethylene glycols are suitable as suppository bases.

For long-term application with a systematic release of the compounds of the present invention up to several weeks, pressed implants are suitable which are preferably formulated on the basis of so-called biodegradable polymers.

As a further important group of systemically active medicaments, transdermal systems are also to be emphasized which distinguish themselves, as with the above-mentioned rectal forms, by circumventing the liver circulation system and/or liver metabolism. These plasters can be especially prepared as transdermal systems which are capable of releasing the compounds of the present invention in a controlled manner over longer or shorter time periods based on different layers and/or mixtures of suitable adjuvants and carriers. Aside from suitable adjuvants and carriers such as solvents and polymeric components, for example based on Eudragit®, membrane infiltration increasing substances and/or permeation promoters, such as for example oleic acid, Azone®, adipinic acid derivatives, ethanol, urea, propylglycol are suitable in the production of transdermal systems of this type for the purpose of improved and/or accelerated penetration.

As topically, locally or regionally administration medicaments, the following are suitable as special formulations: vaginally or genitally applicable emulsions, creams, foam tablets, depot implants, ovular or transurethral administration installation solutions. For ophthalmological application, highly sterile eye ointments, solutions and/or drops or creams and emulsions are suitable.

In the same manner, corresponding otological drops, ointments or creams can be designated for application to the ear. For both of the above-mentioned applications, the administration of semi-solid formulations, such as for example gels based on Carbopols® or other polymer compounds such as for example polyvinylpyrrolidone and cellulose derivatives is also possible.

For customary application to the skin or also to the mucus membrane, normal emulsions, gels, ointments, creams or mixed phase and/or amphiphilic emulsion systems (oil/water-water/oil mixed phase) as well as liposomes and transfersomes can be named. Sodium alginate as a gel builder for production of a suitable foundation or cellulose derivatives, such as for example guar or xanthene gum, inorganic gel builders, such as for example aluminum hydroxides or bentonites (so-called thixotropic gel builder), polyacrylic acid derivatives, such as for example Carbopol®, polyvinylpyrrolidone, microcrystalline cellulose or carboxymethylcellulose are suitable as adjuvants and/or carriers. Furthermore, amphiphilic low and high molecular weight compounds as well as phospholipids are suitable. The gels can be present either as hydrogels based on water or as hydrophobic organogels, for example based on mixtures of low and high molecular paraffin hydrocarbons and vaseline.

Anionic, cationic or neutral tensides can be employed as emulsifiers, for example alkalized soaps, methyl soaps, amine

soaps, sulfanated compounds, cationic soaps, high fatty alcohols, partial fatty acid esters of sorbitan and polyoxyethylene sorbitan, for example lanette types, wool wax, lanolin, or other synthetic products for the production of oil/water and/or water/oil emulsions.

Hydrophilic organogels can be formulated, for example, on the basis of high molecular polyethylene glycols. These gel-like forms are washable. Vaseline, natural or synthetic waxes, fatty acids, fatty alcohols, fatty acid esters, for example as mono-, di-, or triglycerides, paraffin oil or vegetable oils, hardened castor oil or coconut oil, pig fat, synthetic fats, for example based on acrylic, caprinic, lauric and stearic acid, such as for example Softisan® or triglyceride mixtures such as Miglyol® are employed as lipids in the form of fat and/or oil and/or wax-like components for the production of ointments, creams or emulsions.

Osmotically effective acids and bases, such as for example hydrochloric acid, citric acid, sodium hydroxide solution, potassium hydroxide solution, monosodium carbonate, further buffer systems, such as for example citrate, phosphate, Tris-buffer or triethanolamine are used for adjusting the pH value.

Preservatives, for example such as methyl- or propyl benzoate (parabenes) or sorbic acid can be added for increasing stability.

Pastes, powders or solutions are to be mentioned as further topically applicable forms. Pastes often contain lipophilic and hydrophilic auxiliary agents with very high amounts of fatty matter as a consistency-giving base.

Powders or topically applicable powders can contain for example starch varieties such as wheat or rice starch, flame dispersed silicon dioxide or silica, which also serve as

diluents, for increasing flowability as well as lubricity as well as for preventing agglomerates.

Nose drops or nose sprays serve as nasal application forms. In this connection, nebulizers or nose creams or ointments can come to use.

Furthermore, nose spray or dry powder formulations as well as controlled dosage aerosols are also suitable for systemic administration of the compounds of the present invention.

These pressure and/or controlled dosage aerosols and dry powder formulations can be inhaled and/or insufflated. Administration forms of this type also certainly have importance for direct, regional application in the lung or bronchi and larynx. Thereby, the dry powder compositions can be formulated for example as invention compound-soft pellets, as an invention compound-pellet mixture with suitable carriers, such as for example lactose and/or glucose. For inhalation or insufflation, common applicators are suitable which are suitable for the treatment of the nose, mouth and/or pharynx. The compounds of the present invention can also be applied by means of an ultrasonic nebulizing device. As a propellant gas for aerosol spray formulations and/or controlled dosage aerosols, tetrafluoroethane or HFC 134a and/or heptafluoropropane or HFC 227 are suitable, wherein non-fluorinated hydrocarbons or other propellants which are gaseous at normal pressure and room temperature, such as for example propane, butane or dimethyl ether can be preferred. Instead of controlled dosage aerosols, propellant-free, manual pump systems can also be used.

The propellant gas aerosols can also suitably contain surface active adjuvants, such as for example isopropyl myristate, polyoxyethylene sorbitan fatty acid ester, sorbitan trioleate, lecithins or soya lecithin.

In addition, when the pharmaceutical composition of the present invention comprises a nucleic acid of the invention for administration to a certain species of animal, the nucleic acid of the invention is preferably derived from that species. For example, when the pharmaceutical composition of the present invention is to be administered to humans, the nucleic acid of the pharmaceutical preferably comprises the coding region of a member of the CD83 family of proteins or a derivative thereof.

The nucleic acids of the invention can be administered in conjunction with agents that increase cell membrane permeability and/or cellular uptake of the nucleic acids. Examples of these agents are polyamines as described for example by Antony, T. et al. (1999) *Biochemistry* 38: 10775-10784; branched polyamines as described for example by Escriou, V. et al. (1998) *Biochem. Biophys. Acta* 1368(2): 276-288; polyaminolipids as described for example by Guy-Caffey, J.K. et al. (1995) *J. Biol. Chem.* 270(52): 31391-31396; DOTMA as described by Felgner, P.L. et al. (1987) *PNAS USA* 84(21): 7413-7417 and cationic porphyrins as described for example by Benimetskaya, L. et al. (1998) *NAR* 26(23): 5310-5317.

A nucleic acid molecule according to the invention or a nucleic acid that encodes a protein according to the invention may be inserted into a vector. The term "vector" refers to a plasmid, virus or other vehicle known in the art that can be manipulated by insertion or incorporation of a polynucleotide. Such vectors can be used for genetic manipulation (i.e., "cloning vectors") or can be used to transcribe or translate the inserted polynucleotide ("expression vectors"). A vector generally contains at least an origin of replication for propagation in a cell and a promoter. Control elements, including expression control elements as set forth herein, present within an expression vector are included to facilitate proper transcription and translation (e.g., splicing signal for introns, maintenance

of the correct reading frame of the gene to permit in-frame translation of mRNA and, stop codons etc.). The term "control element" is intended to include, at a minimum, one or more components whose presence can influence expression, and can also include additional components, for example, leader sequences and fusion partner sequences.

As used herein, the term "expression control element" refers to one or more nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. An expression control element operatively linked to a nucleic acid sequence controls transcription and, as appropriate, translation of the nucleic acid sequence. Thus an expression control element can include, as appropriate, promoters, enhancers, transcription terminators, a start codon (e.g., ATG) in front of a protein-encoding gene. "Operatively linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.

By "promoter" is meant a minimal sequence sufficient to direct transcription. Both constitutive and inducible promoters are included in the invention (see e.g., Bitter et al., Methods in Enzymology 153:516-544, 1987). Inducible promoters are activated by external signals or agents. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for specific cell-types, tissues or physiological conditions; such elements may be located in the 5', 3' or intronic regions of the gene. Promoters useful in the invention also include conditional promoters. A "conditional promoter" is a promoter which is active only under certain conditions. For example, the promoter may be inactive or repressed when a particular agent, such as a chemical compound, is present. When the agent is no longer present, transcription is activated or derepressed.

Thus, when cloning in bacterial systems, constitutive promoters such as T7 and the like, as well as inducible promoters such as pl, of bacteriophage X, plac, ptrp, ptac (ptrp-lac hybrid promoter) may be used. When cloning in mammalian cell systems, constitutive promoters such as SV40, RSV, CMV including CMV-IE, and the like or inducible promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the mouse mammary tumor virus long terminal repeat; the adenovirus late promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.

Mammalian expression systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression vectors, nucleic acid of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. Alternatively, the vaccinia virus 7.5K promoter may be used.

Of particular interest are vectors based on bovine papilloma virus (BPV) which have the ability to replicate, as extrachromosomal elements. Shortly after entry of an extrachromosomal vector into mouse cells, the vector replicates to about 100 to 200 copies per cell. Because transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, a high level of expression occurs. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as the neo gene, for example. Alternatively, the retroviral genome can be modified for use as a vector capable of introducing and directing the expression of the nucleic acid of interest in host cells. High level expression may also be achieved using inducible promoters, including,

but not limited to, the metallothionein RA promoter and heat shock promoters.

In yeast, a number of vectors containing constitutive or inducible promoters may be used. A constitutive yeast promoter such as ADH or LEU2 or an inducible promoter such as GAL may be used. Alternatively, vectors that facilitate integration of foreign nucleic acid sequences into a yeast chromosome, via homologous recombination for example, are known in the art and can be used.

A nucleic acid of interest according to the present invention may be inserted into an expression vector for expression in vitro (e.g., using in vitro transcription/translation assays or commercially available kits), or may be inserted into an expression vector that contains a promoter sequence which facilitates transcription and/or translation in either prokaryotes or eukaryotes (e.g., an insect cell) by transfer of an appropriate nucleic acid into a suitable cell. A cell into which a vector can be propagated and its nucleic acid transcribed, or encoded polypeptide expressed, is referred to herein as a "host cell". The term also includes any progeny of the subject host cell. Moreover, a nucleic acid of interest according to the present invention may be inserted into an expression vector for expression in vivo for somatic gene therapy for example. With these vectors, for example, retroviral vectors, lentivirus vectors, Adenovirus vectors, Adeno-associated virus vectors, plasmid expression vectors, the nucleic acids of the invention are expressed upon infection/introduction of the vector into DC.

Host cells include but are not limited to microorganisms such as bacteria, yeast, insect and mammalian organisms. For example, bacteria transformed with recombinant bacteriophage nucleic acid, plasmid nucleic acid or cosmid nucleic acid expression vectors containing a nucleic acid of interest; yeast transformed with recombinant yeast expression vectors

containing a nucleic acid of interest; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing a nucleic acid of interest; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing a nucleic acid of interest; or animal cell systems infected with recombinant virus expression vectors (e.g., retroviruses, lentivirus, adenovirus, vaccinia virus) containing a nucleic acid of interest, or transformed animal cell systems engineered for stable expression.

For long-term expression of invention polypeptides in host cells, stable expression is preferred. Thus, using expression vectors which contain viral origins of replication, for example, cells can be transformed with a nucleic acid of interest controlled by appropriate control elements (e.g., promoter/enhancer sequences, transcription terminators, polyadenylation sites, etc.). Optionally, the expression vector also can contain a nucleic acid encoding a selectable or identifiable marker conferring resistance to a selective pressure thereby allowing cells having the vector to be identified, grown and expanded. Alternatively, the selectable marker can be on a second vector that is cotransfected into a host cell with a first vector containing an invention polynucleotide.

A number of selection systems may be used, including, but not limited to the herpes simplex virus thymidine kinase gene, hypoxanthine-guanine phosphoribosyltransferase gene, and the adenine phosphoribosyltransferase genes can be employed in tk-, hgp^rt or ap^rt cells respectively. Additionally, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate; the gpt gene, which confers resistance to mycophenolic acid; the neomycin gene, which confers resistance to the

aminoglycoside G-418; and the hygromycin gene, which confers resistance to hygromycin. Additional selectable genes have been described, namely *trpB*, which allows cells to utilize indole in place of tryptophan; *hisD*, which allows cells to utilize histinol in place of histidine; and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO.

As used herein, the term "transformation" means a genetic change in a cell following incorporation of DNA exogenous to the cell. Thus, a "transformed cell" is a cell into which (or a progeny of which) a DNA molecule has been introduced by means of recombinant DNA techniques.

Transformation of a host cell with DNA may be carried out by conventional techniques known to those skilled in the art. For example, when the host cell is a eukaryote, methods of DNA transformation include, for example, calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, and viral vectors. Eukaryotic cells also can be cotransformed with DNA sequences encoding a nucleic acid of interest, and a second foreign DNA molecule encoding a selectable phenotype, such as the those described herein. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein.

When the compound of the invention is an RNA molecule, said RNA molecule can be delivered to the cells of a subject by transforming said cells with an expression vector that comprises a nucleotide sequence encoding said RNA molecule under control of sequence that allows for the transcription of the nucleotide sequence.

Thus, the present invention relates to an expression vector comprising a nucleic acid sequence encoding an RNA according to the invention that specifically blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduces expression of a member of the CD83 family of proteins in a cell.

Preferably, the expression vector is constructed such that the RNA molecule is not translated into a polypeptide or protein in a cell.

Furthermore, the present invention relates to a host cell transformed with the above mentioned expression vector..

The present invention also relates to the use of an expression vector encoding an nucleic acid according to the invention that specifically blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduces expression of a member of the CD83 family of proteins in a cell for the production of a medicament for the treatment and prevention of disorders, diseases and syndromes involving the direct or indirect participation of DC by regulating an immune response..

Furthermore, the invention relates to a method of treatment or prevention of disorders, diseases and syndromes involving the direct or indirect participation of dendritic cells by regulating an immune response, wherein an effective amount of an expression vector encoding an nucleic acid according to the invention that specifically blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduces expression of a member of the CD83 family of proteins in a cell is administered to a subject.

When the compound of the invention is protein, said protein molecule can be delivered to the cells of a subject by transforming said cell with an expression vector that comprises a nucleotide sequence encoding said protein under control of sequence that allows for the transcription of the nucleotide sequence.

Thus, the present invention relates to an expression vector comprising a nucleic acid sequence encoding a derivative of a member of the ELAV superfamily of proteins or a derivative of a ligand to HuR that specifically blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduces expression of a member of the CD83 family of proteins in a cell.

Furthermore, the present invention relates to a host cell transformed with the above mentioned expression vector.

The present invention also relates to the use of an expression vector encoding a derivative of a member of the ELAV superfamily of proteins or a derivative of a ligand to HuR that specifically blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduces expression of a member of the CD83 family of proteins in a cell for the production of a medicament for treating any of the medical indications mentioned above.

Furthermore, the invention relates to a method of treatment or prevention of disorders, diseases and syndromes involving the direct or indirect participation of dendritic cells by regulating an immune response wherein an effective amount of an expression vector encoding a derivative of a member of the ELAV superfamily of proteins or a ligand to HuR that specifically blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83

family of proteins and that reduces expression of a member of the CD83 family of proteins in a cell is administered to a subject.

The present invention also relates to a method for screening and/or identifying compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins comprising the steps of incubating one or more compounds in a reaction comprising:

- (a) a nucleic acid molecule that contains at least a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof and
- (b) a member of the ELAV superfamily of proteins or derivative thereof

under conditions sufficient to allow the components to interact and determining whether the compound blocks the binding between the nucleic acid molecule and the member of the ELAV superfamily of proteins.

As used herein, the term "incubating" refers to conditions that allow the contact, binding or interaction between (a) and (b) above and the test compound. The term "contacting" includes in solution, in solid phase and in cells.

Both the nucleic acid molecule that contains at least a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof and the member of the ELAV superfamily of proteins or derivative thereof that are used in this method are defined as above.

A given compound can be considered to block the binding between the nucleic acid molecule and the member of the ELAV superfamily of proteins when said compound blocks the high-affinity and specific binding of HuR to the stem-loop structure of CD83 mRNA.

Compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins are identified by determining an activity of a protein from the CD83 family of proteins or the expression of a member of the CD83 family of proteins in the presence and in the absence of a test compound. An activity of a protein from the CD83 family of proteins or the expression of a member of the CD83 family of proteins, can be determined using cell free systems, in cells and in a whole organism. For example, electrophoretic mobility shift assays (EMSA) as described in the examples can be used to identify a compound that blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins. In cells, compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins can be identified by treating cells that express a mRNA encoding a member of the CD83 family of proteins with a test compound, and then examining the phenotype of said cells for functional expression of the member of the CD83 family of proteins.

Compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins can be identified by detecting the expression of a mRNA comprising a reporter gene sequence linked to a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof (i. e., a functional analysis as provided in the examples). The reporter provides a detection signal (e.g., the amount of transcript or protein product produced by the reporter gene) that corresponds to the degree of binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins. A compound "blocks" binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins if the detection signal provided by the reporter gene is decreased as compared with the signal in the absence of the test

compound. A compound "inhibits" binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins if the signal is decreased as compared with the signal in the absence of the test compound.

The signal provided by the reporter gene can be, for example, RNA, protein, an enzymatic activity and the like. Thus, the signal can be detected by a variety of methods known in the art, including northern analysis, RNA dot blots, ELISA or RIA, Western blots, SDS-PAGE alone, or in combination with antibodies that immunoprecipitate the reporter gene product. Expressed products that provide an enzymatic activity or detection signal are preferred and include, for example, β -galactosidase, alkaline phosphatase, horseradish peroxidase, luciferase, green fluorescent protein and chloramphenicol acetyl transferase. Cells contemplated for use in these methods include the cells describe herein, for example, insect cells, mammalian cells (e.g., CV-1, COS, HeLa and L-cells) and yeast cells.

Test compounds that may effect binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins are found among biomolecules including, but not limited to: nucleic acids, proteins, peptides, polypeptides, peptidomimetics, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives thereof, structural analogs thereof or combinations thereof. Test compounds further include chemical compounds (e.g., small organic molecules having a molecular weight of more than 50 and less than 5,000 Daltons, such as hormones). Candidate organic compounds comprise functional groups necessary for structural interaction with proteins or nucleic acids, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate organic compounds often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic

structures substituted with one or more of the above functional groups. Known pharmacological compounds are candidates that may further be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc., to produce structural analogs.

Test compounds can additionally be contained in libraries, for example, synthetic or natural compounds in a combinatorial library. Numerous libraries are commercially available or can be readily produced; means for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides, also are known. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or can be readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Such libraries are useful for the screening of a large number of different compounds.

A variety of other compounds may be included in the screening method. These include agents like salts, neutral proteins, e.g., albumin, detergents, etc. that are used to facilitate optimal protein-protein, protein-nucleic acid or nucleic acid-nucleic acid binding or interactions and/or reduce nonspecific or background binding or interactions. For example, reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, antimicrobial agents, etc., may be used. The mixture of components is added in any order that provides for the requisite modulation. Moreover, such test compounds additionally can be modified so as to facilitate their identification or purification. Such modifications are well

known to the skilled artisan (e.g., biotin and streptavidin conjugated compounds).

Incubations are performed at any suitable temperature, typically between 4 and 40°C. Incubation periods are selected for optimum activity, but may also be chosen to facilitate rapid high-throughput screening. Typically, between 0.1 and 72 hours incubation time will be sufficient.

In preferred embodiments of the invention, the method for screening and/or identifying compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins can be carried out in the form of RNA gel shift assays, filter binding assays, Biacore interaction analysis (Biacore, Uppsala, Sweden), Scintillation Proximity Assay (Amersham Pharmacia Biotech, Freiburg, Germany), RNase protection assays, cell-based RNA binding assays (see Blair et al. (1998) RNA 4: 215-225), yeast 3-hybrid assays (for example, RNA-Protein Hybrid Hunter[®] System (Invitrogen, Groningen, The Netherlands)), and reporter gene assays in eukaryotic cells as described above.

In the following, various aspects of the invention are more closely described via examples. However, the invention should not be considered as being to the examples.

Detailed description of the invention

Example 1

RNA mobility shift experiments are a very sensitive method for characterizing RNA-protein interactions. For this, the RNA to be examined can be amplified and radioactively labeled with the aid of in vitro transcription from a linear DNA template. The labeling generally occurs with [α -³²P]-UTP. In order to ensure the correct folding of the RNA, this is

heated in a water bath to 80°C and cooled to room temperature. RNA obtained in this manner is then incubated with the desired protein and subsequently analyzed on a native polyacrylamide gel, i.e. under non-denaturing conditions.

In order to examine whether a mRNA encoding a member of the CD83 family of proteins specifically binds to a member of the HuR family of proteins, a vector, pCDNA3-CD83, was constructed in which nucleotides 1 to 618 of SEQ ID NO:1 were inserted into the HindIII-EcoRI sites of the commercially available vector pCDNA3 (Invitrogen, Groningen, The Netherlands) under the control of a phage T7 promoter (Figure 1).

In order to obtain radioactively labeled RNA for the RNA mobility shift experiments, approximately 20 µg of this vector were linearized with EcoRI and purified on a 0.8% agarose gel. After elution from the gel, the template was extracted with phenol and ethanol precipitated. The resulting DNA was resuspended at a concentration of 1.0 µg/ml in 20 µl nuclease-free water. Radioactively labeled RNA was generated using a Riboprobe In Vitro Transcription System (Promega, Heidelberg, Germany) according to the instructions of the manufacturer using [α -³²P]-UTP. The transcription products were controlled for size and purity by separating 1 µl of the in vitro transcription reaction on a denaturing RNA agarose gel (1.2%), blotting the gel to a nitrocellulose membrane (Amersham-Pharmacia, Freiburg, Germany) for 8 hours and examining the nitrocellulose filter with the aid of photographic film using RNA size standards.

Plasmid pGEX5X-1-GST-ELAV encoding a recombinant GST-ELAV (HuR) fusion protein (GST: glutathione-S-transferase) was constructed by cloning nucleotides 1 to 931 of SEQ ID NO:5 into the EcoRI and XhoI sites of the commercially available

plasmid pGEX-5X-1 (Amersham-Pharmacia, Freiburg, Germany) (Figure 2).

A recombinant GST-ELAV (HuR) fusion protein was obtained by isolating the protein from *E. coli* BL21 (Stratagene GmbH, Heidelberg, Germany) transformed with plasmid pGEX5X-1-GST-ELAV. On the day before isolation, the bacterium was grown in a 50 ml pre-culture. On the following day, this pre-culture was diluted 1:10 in LB medium and incubated until an OD₆₀₀ of approximately 0.5-0.6. The induction of fusion protein occurred by addition of IPTG (final concentration 1 mM). After 4 hours, the culture was cooled on ice and then centrifuged at 5000 rpm in a Sorvall GSA rotor for 10 min at 4°C. The pellet was then suspended in 10 ml of a buffer comprising 50 ml PBS, 100 µl PMSF, 50 µl leupeptin, 50 µl pepstatin, 50 µl aprotinin and 50 µl DNase I. After addition of 26 µl of 1 M MnCl₂, 260 µl of 1 M MgCl₂ and a spatula tip of lysozyme, the suspension was briefly mixed and left on ice for 15 min. This was then sonicated 3 times for 10 sec. (2 impulses per second/max. output) and was adjusted to a final sodium chloride concentration of 0.5 M NaCl. To completely lyse the cells, Triton TX-100 was added to a concentration of 1% and the suspension was held on ice for 10 min. Finally the cell residue was centrifuged at 14,000 rpm in a Sorvall SS34 rotor for 30 min. at 4°C.

750 µl of glutathione-Sepharose (Amersham-Pharmacia, Freiburg, Germany) was washed 3 times with 10 ml of PBS. The supernatant of the bacterial cell extraction and the glutathione-Sepharose were mixed and incubated on a rotating shaker placed in a refrigerator for 1 hour. The glutathione-Sepharose, cell extract mixture was placed on a Bio-Prep column (BioRad, Munich, Germany) and washed 3 times each with 5 ml of a buffer consisting of 15 ml PBS 1 ml Triton TX-100 (20% stock solution) and 3 times each with a buffer consisting of 15 ml PBS and 50 µl PMSF. The elution of the GST-HuR fusion protein from the glutathione-Sepharose

occurred in five elution steps each with 1 ml of a buffer comprising 50 mM Tris base, 150 mM NaCl and 15 mM glutathione. 1 ml of this elution buffer was added to the column, the column was closed and then incubated for 10 minutes on a rotating platform. The protein solutions were then combined and dialyzed for 12 hours against PBS.

RNA mobility shift experiments were then carried out using the radioactively labeled CD83 RNA and the GST-ELAV (HuR) fusion protein as described above. 1 μ l of approximately 150-200 ng/ml radioactively labeled CD83 RNA and 1 μ l of GST-ELAV (HuR) (protein concentration: 0.3 mg/ml) were used per reaction. Alternatively, GST protein without ELAV sequences was used as a control. The radioactively labeled CD83 RNA was heated to 80°C in a water bath and cooled to room temperature directly before the reaction. The GST-ELAV (HuR) fusion protein (or GST control protein directly expressed from the vector pGEX-5X-1 was carefully mixed with a binding mixture consisting of 1 μ l radioactively labeled CD83 RNA, 1 μ l Rnasin® RNase inhibitor (diluted 5:1 in PBS), 1 μ l 10 x PBS and 6 μ l MS2 RNA or 5S RNA (Roche Diagnostics, Mannheim, Germany) (0.8 μ g/ μ l) and incubated at room temperature for 30 min. 3 μ l of 50% glycerin were added to each reaction to ease loading and analysis of the binding between the GST-ELAV (HuR) fusion protein and the CD83 RNA occurred on a 4% or 6% native polyacrylamide gel with a TBE running buffer of pH 8.3.

As can be seen from Figure 3, the GST-ELAV (HuR) protein shifted the CD83 RNA to a higher position in the gel, whereas no shift occurred in the reaction comprising CD83 RNA and the GST protein control.

Example 2

As a control for the specificity of the interaction between HuR and CD83 mRNA, RNA mobility shifts as described in

Example 1 were performed using the GST protein as described above, a GST-L5 fusion protein (Schatz et al. (1998) PNAS USA 95: 1607-1612), and a GST- M9 fusion protein comprising the M9 domain of the heterogeneous nuclear ribonucleoprotein hnRNP A1 (Pollard, V.W. et al. (1996) Cell 86: 985-994).

As can be seen in Figure 4, a shift in the mobility of the CD83 RNA is only observed with protein comprising the HuR sequence.

Example 3

A standard method to test the specificity of a nucleic acid-protein interaction demonstrated in a RNA mobility shift experiment is to compete binding of the radioactively labeled RNA to the protein with unlabeled RNA. For this, the binding mixture as described above was produced with increasing amounts of non-radioactive CD83 RNA and the RNA mobility shift experiments were carried out as described above, except that the binding mixture was incubated with the respective protein for 15 min and then the same amount of radioactively labeled CD83 RNA (1 μ l) was subsequently added to each reaction and incubation was continued for a further 15 min.

The results of this experiment are shown in Figure 5. It was demonstrated that unlabeled CD83 RNA is capable of titrating free GST-ELAV (HuR) protein.

Example 4

Having established that the binding of HuR to CD83 mRNA is specific, several experiments were conducted to determine and delineate the region of the CD83 mRNA to which HuR binds.

In order to delineate the region of CD83 mRNA to which HuR binds, the coding region of CD83 or sub-fragments of the CD83 coding sequence were cloned into the HindIII and/or EcoRI

restriction sites in the multiple cloning site of the vector pcDNA3 under control of the phage T7 promoter. These sub-fragments were generated using a standard PCR reaction as described above and the following primers:

Sub-fragment CD83 nt1-nt294 (= aa1-aa98):

5' primer; introduces HindIII site and start codon:

5'-ATTTAAAAGCTTATGTCGCGCGCCTCCAGCTTCTG-3'

(SEQ ID NO:7) and

3' primer; introduces EcoRI site and stop codon:

5'-ATTTAAGAATTCTCAGGTAGTGTTCGGATCTTCAGGGAATA-3'

(SEQ ID NO:8);

Sub-fragment CD83 nt202-nt414 (= aa68-aa138):

5' primer; introduces HindIII site and start codon:

5'-ATTTAAAAGCTTATGCTCAGGGGACAGCACTATCATCAGAAG-3'

(SEQ ID NO:9) and

3' primer; introduces EcoRI site and stop codon:

5'-ATTTAAGAATTCTCAAAAAGTCTCTTCTTTACGCTGTGCAGGGC-3'

(SEQ ID NO:10);

Sub-fragment CD83 nt295-nt618 (= aa99-aa205):

5' primer; introduces HindIII site and start codon:

5'-ATTTAAAAGCTTATGAGCTGCAACTCGGGGACATACAGG-3'

(SEQ ID NO:11) and

3' primer; introduces EcoRI site:

5'-ATTTAAGAATTCTCATACCAGTTCTGTCTTGTGAGGAGTCAC-3'

(SEQ ID NO:12).

The PCR reaction mix was composed of the following components:

10 μ l template DNA (100 ng; 0.01 μ g/ μ l)
10 μ l 10 x polymerase buffer
(Roche Diagnostics, Mannheim, Germany).
10 μ l dNTP mix (each NTP 2mM)
2.5 μ l primer 1 (0.1 μ g/ μ l)
2.5 μ l primer 2 (0.1 μ g/ μ l).
64 μ l water
1 μ l PWO polymerase (Roche Diagnostics, Mannheim, Germany)

The PCR was carried out in a thermostable heating block with cover heating (Genius Thermocycler, Techne, NJ, USA). The amplification occurred in 45 cycles wherein the programmed cycles were as follows: the first cycle was performed with a denaturation step at 95°C for 3 min., a step for hybridization of the primers at 52°C for 2 min. and a synthesis reaction at 72°C for 6 min.; the remaining 44 cycles were performed with a denaturation step at 95°C for 1 min., a step for hybridization of the primers at 65°C for 1 min. and a synthesis reaction at 72°C for 4 min., whereby the time for each ensuing synthesis reaction was increased by 1 second; at the end of the program, a synthesis step was performed at 72°C for 10 min.

The resulting vectors were linearized with EcoRI and radioactively labeled RNA was produced and employed in RNA mobility shift assays as described above.

The results are shown in Figure 6 and demonstrate that a region of HuR binding to CD83 mRNA is found from nucleotide 415 to nucleotide 618 of (SEQ ID NO:1).

Example 5

The secondary structure of a nucleic acid can be calculated at a certain temperature with the aid of the program MFOLD of

the Genetics Computer Group (GCG) of the University of Wisconsin, USA (<http://www.gcg.com>).

A DNA sequence containing nucleotides 412 to 618 of SEQ ID NO:1 encoding the amino acids 138-205 of CD83 was used as input data in the MFOLD program to calculate the secondary structure of the corresponding RNA molecule. A folding temperature of 37°C, a maximum size of interior loop of 30 and maximum loopsideness of an interior loop of 30 was used. The most probable secondary structure based on this calculation, i.e. the secondary structure having the most negative energy in kcal/mol is presented in Figure 7 (-41.8 kcal/mol); the second most probable in Figure 8 (-41.7 kcal/mol) and the third most probable in Figure 9 (-40.8 kcal/mol).

Each of these secondary structures has two clearly recognizable domains: a first domain (stem-loop-1) comprising a single stem-loop structure and containing the CD83 RNA sub-fragment from nucleotide 412 to nucleotide 465 of SEQ ID NO:1 and a further, second domain (stem-loop-2) comprising a single 3-pronged stem-loop structure and containing the CD83 RNA sub-fragment from nucleotide 466 to nucleotide 618 of SEQ ID NO:1.

Example 6

In order to further characterize the HuR binding domain on the CD83 mRNA, the first domain

In order to further delineate the region of CD83 mRNA to which HuR binds, the domain stem-loop-1 comprising a single stem-loop structure and containing the CD83 RNA sub-fragment from nucleotide 295 to nucleotide 465 of SEQ ID NO:1 and the stem-loop-2 domain comprising a single 3-pronged stem-loop structure and containing the CD83 RNA sub-fragment from nucleotide 466 to nucleotide 618 of SEQ ID NO:1 were cloned

into the HindIII and/or EcoRI restriction sites in the multiple cloning site of the vector pCDNA3 under control of the phage T7 promoter. These sub-fragments were generated using a standard PCR reaction as described above and the following primers:

Sub-fragment CD83 nt295-nt465 (= aa99-aa155):

5' primer; introduces HindIII site and start codon:

5'-ATTTAAAAGCTTATGAGCTGCAACTCGGGGACATACAGG-3'

(SEQ ID NO:11) and

3' primer; introduces EcoRI site and stop codon:

5'-ATTTAAGAATTCTCAGTAGAAAATAACCAGAGCCAGCAGCAGG-3'

(SEQ ID NO:13);

Sub-fragment CD83 nt466-nt618 (aa156-aa205):

5' primer; introduces HindIII site and start codon:

5'-ATTTAAAAGCTTATGTTAACACTCATCATTTTCACTTGTAAGTTTGC-3'

(SEQ ID NO:14) and

3' primer; introduces EcoRI site:

5'-ATTTAAGAATTCTCATACCAGTTCTGTCTTGTGAGGAGTCAC-3'

(SEQ ID NO:12).

The resulting vectors were linearized with EcoRI and radioactively labeled RNA was produced and employed in RNA mobility shift assays as described above.

The results are shown in Figure 10 and demonstrate that HuR can bind to both the stem-loop-1 and stem-loop-2 domain of the CD83 RNA.

Example 7

In order to determine whether the binding of HuR to CD83 mRNA leads to a biologically significant effect, a reporter plasmid, pB12/CMV/CAT, was constructed by cloning the chloramphenicol transferase gene (CAT) under the transcriptional control of the cytomegalovirus immediate early promoter (CMV-IE) and inserting the coding region of CD83 downstream of the CAT gene followed by a poly(A) site. The plasmid pBC12/HIV/CAT (Berger, J. et al. (1988) Gene 66: 1-10) was digested with HindIII and BamHI in order to isolate a DNA fragment containing the CAT gene. The plasmid pBC12/CMV/ β -Gal/SD-SA was also digested with HindIII and BamHI and the HindIII and BamHI digested CAT gene was inserted into HindIII and BamHI digested plasmid pBC12/ β -Gal/SD-SA such that the β -Gal of pBC12/CMV/ β -Gal/SD-SA was replaced by the CAT gene. This CAT containing vector was then digested with BamHI and XmaI in order to remove the SD-SA region and various sub-fragments of the CD83 gene were cloned into this BamHI and XmaI digested vector (see Figure 11. A CAT containing vector without CD 83 sequences was also constructed as a negative control for some experiments by filling in the 5' overlapping ends created by digestion with BamHI and XmaI with Klenow fragment and ligating these ends together.

A series of CD83 sub-fragments without start and stop codons were obtained using the following primers or oligonucleotides in a standard PCR reaction as described above and were ligated into the BamHI and XmaI sites in the 3' non-translated region of the CAT gene of the above pBC12 vector:

Sub-fragment CD83 nt412-nt615 (= aa138-aa205):

5' primer; introduces BamHI site:

5'-ATTTAAGGATCCTTTAAGAAATACAGAGCGGAGATTGTCCTG-3'

(SEQ ID NO:15) and

3' primer; introduces XmaI site:

5'-ATTTAACCCGGGTACCAGTTCTGTCTTGTGAGGAGTCACTAG-3'
(SEQ ID NO:16);

Sub-fragment CD83 nt412-nt615 (= aa138-aa205) antisense

5' primer; introduces XmaI site:

5'-ATTTAACCCGGGTTTAAGAAATACAGAGCGGAGATTGTCCTG-3'
(SEQ ID NO:17) and

3' primer; introduces BamHI site:

5'-ATTTAAGGATCCTACCAGTTCTGTCTTGTGAGGAGTCACTAG-3'
(SEQ ID NO:18);

Sub-fragment CD83 nt412-nt465 (= aa138-aa155)

Oligos for direct annealing:

5' primer; introduces BamHI site:

5'-GATCCTTTAAGAAATACAGAGCGGAGATTGTCCTGCTGCTGGCTC...
TGGTTATTTTCTACC-3' (SEQ ID NO:19) and

3' primer; introduces XmaI site:

5'-GAAATTCTTTATGTCTCGCCTCTAACAGGACGACGACCGAGACCA...
ATAAAAG-3' (SEQ ID NO:20);

Sub-fragment CD83 nt466-nt615 (= aa156-aa205):

5' primer; introduces BamHI site:

5'-ATTTAAGGATCCTTAACACTCATCATTTTCACTTGTAAGTTTGC-3'
(SEQ ID NO:21) and

3' primer; introduces XmaI site:

5'-ATTTAACCCGGGTACCAGTTCTGTCTTGTGAGGAGTCACTAG-3'
(SEQ ID NO:16).

These vectors were then transiently transfected into COS cells (ATCC number:CRL-1650) via DEAE dextran transfection. Briefly, 6-well culture dishes (Corning, Corning, USA) were treated with 0.1% gelatin for 20 min. at room temperature and then washed twice with PBS. 2.5×10^5 COS cells were seeded in 4 ml culture medium (DMEM (Gibco, Karlsruhe, Germany) with 10% fetal calf serum, 1% non-essential amino acids, 1% glutamine and 1% penicillin/streptomycin) and cultured overnight. All DNAs to be transfected were brought to a final concentration of 0.025 $\mu\text{g/ml}$. In a sterile Eppendorf tube, 25 μl of the DNA solution containing the CD83 constructs were mixed with pBC12/CMV vector to obtain a final DNA concentration of 2.5-3.0 $\mu\text{g/ml}$. 225 μl of a DEAE dextran solution (62.5 μl of DEAE dextran stock solution (20 mg/ml) in 2.24 ml PBS) was added to the 25 μl DNA solution and this was carefully added directly to the COS cells after the culture medium was removed and the cells were washed twice with 37°C PBS. The transfection reactions were allowed to progress for 30 min in an incubator (37°C, 5% CO_2 , 80% humidity). Then, 2.5 ml of FC medium (20 ml of the DMEM medium described above with 400 μl fungizone (2%) and 20 μl chloroquine (100 mM) were added to each well and the cells were incubated for a further 2.5 hours at 37°C, 5% CO_2 , 80% humidity. The DNA/FC medium mixture was then aspirated and each well received 1 ml of shock medium consisting of 9 ml the DMEM culture medium described above and 1 ml DMSO. After 2.5 min. incubation at room temperature, the shock medium was aspirated and replaced by culture medium. Incubation continued for 48-72 hours at 37°C, 5% CO_2 , 80% humidity.

In order to exclude erroneous results generated by different transfection efficiencies, each transfection was performed with the same amount of an internal control vector constructed by digesting the vector pBC12/CMV/ β -Gal/SD-SA with BamHI and XmaI, filling in the 5' overlapping ends with Klenow fragment (Roche Diagnostics, Mannheim, Germany) and religating the vector.

Lysis of the COS cells transfected in this manner occurred with the cell lysis buffer of the CAT ELISA kit of Roche Diagnostics, Mannheim, Germany, in accordance with the manufacturer's instructions.

Evaluation of the assay was performed by CAT ELISA and β -Gal assay.

For the CAT ELISA, 200 μ l of transfected cell extract was used and the measurement of the color reaction occurred after 30 min. in an ELISA microplate reader at the wave lengths of 405 nm and 490 nm (reference).

For the β -Gal assay, 25 μ l of transfected cell extract was added to 200 μ l of Working Z buffer (10 ml Z buffer (16,1 gr $\text{Na}_2\text{HPO}_4 \cdot 7 \text{H}_2\text{O}$, 5,5 gr $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$, 0,75 gr KCl, 0,25 gr $\text{MgSO}_4 \cdot 7 \text{H}_2\text{O}$ in 1 liter water, to pH 7.0) to which 8 μ l of 10 % SDS and 28 μ l β -mercaptoethanol are added directly before use) in a 96 well microtiter plate. Then, 25 μ l CPRG (chlorophenol red- β -D-galactopyranoside (Roche Diagnostics, Mannheim, Germany); 15 mg dissolved in 1 ml H_2O) was added and after about 10 min., measurement occurred using an ELISA reader at a wave length of 560 nm..

In the following experiments, the CAT activity is given with respect to the β -Gal activity. The background activity was measured by transformation of the cells with a plasmid without a CAT gene and was subtracted from the measured values to obtain a normalized CAT activity. Unless otherwise noted, the experiments were carried out at least 5 times for statistical evaluation.

Example 8

In order to ascertain whether a difference in the measured CAT activity exists between a reporter construct with and

without a CD83 insert, transfection experiments were first carried out with the CAT containing vector without CD83 sequences (see Example 7) and the CAT containing vector with the CD83 insert from nucleotides 412 to 615 of SEQ ID NO:1.

An approximate two-fold decrease in the CAT activity from the vector with the CD83 insert from nucleotides 412 to 615 of SEQ ID NO:1 was observed in comparison to the CAT containing vector without CD83 sequences (see Figure 12).

In order to determine a possible effect of HuR on the observed CAT activity of a CAT containing vector with a CD83 insert, COS cells were co-transfected with the same amounts of the plasmid pcDNA-ELAV (HuR) and the vector with the CD83 insert from nucleotides 412 to 615 of SEQ ID NO:1. The vector pcDNA3-ELAV (HuR) comprises the coding region of HuR as given in SEQ ID NO:5 cloned into the HindIII and XhoI sites of pcDNA3 under control of the CVM-IE promoter.

As can be seen from Figure 13, an approximate two-fold increase in CAT activity was measured with co-transfection of the ELAV (HuR) vector as compared to transfection with the vector with the CD83 insert from nucleotides 412 to 615 of SEQ ID NO:1 alone.

In addition to the above, in experiments using a CAT containing vector with the CD83 insert from nucleotides 412 to 615 of SEQ ID NO:1 in the sense or antisense orientation, it could be demonstrated that a) the CAT containing vector with the sense orientation of the CD83 sequence has an approximately 5-fold greater CAT activity than the antisense vector in COS cells which were not transfected with the pcDNA-ELAV (HuR) plasmid and b) the CAT activity of the vector with the CD83 insert from nucleotides 412 to 615 of SEQ ID NO:1 in the sense orientation is increased approximately two-fold by co-transfection with the pcDNA-ELAV

(HuR) plasmid as compared to the CAT activity of the antisense vector (see Figure 14).

Moreover, in experiments in which COS cells were transiently transfected using a CAT containing vector with the CD83 insert from nucleotides 412 to 615 of SEQ ID NO:1, a CAT containing vector with the CD83 insert from nucleotides 412 to 465 of SEQ ID NO:1 (stem-loop-1) or a CAT containing vector with the CD83 insert from nucleotides 466 to 615 of SEQ ID NO:1 (stem-loop-2), with or without the pCDNA-ELAV (HuR) plasmid, it could be demonstrated that the CAT containing vectors with stem-loop-2 (i.e. comprising nucleotides 412 to 615 of SEQ ID NO:1 or nucleotides 466 to 615 of SEQ ID NO:1) lead to an approximately two-fold greater CAT activity when COS cells were co-transfected with the pCDNA-ELAV (HuR) plasmid as compared to the CAT activity of COS cells that were transfected with CAT containing vectors with stem-loop-2 alone (see Figure 15).

No HuR-dependent effect could be shown for the CAT containing vector with the CD83 insert from nucleotides 412 to 465 of SEQ ID NO:1 (stem-loop-1).

Summarizing the above results, it was demonstrated that the HuR protein is capable of specifically binding to an RNA molecule that comprises at least a portion of the nucleotide sequence coding for a region of the CD83 protein from nucleotides 466 to 615 of SEQ ID NO:1. Furthermore, it was demonstrated in an in vitro transient expression system that the over-expression of HuR leads to an increase in the amount of protein expressed from a mRNA molecule comprises at least a portion of the nucleotide sequence coding for a region of the CD83 protein from nucleotides 466 to 615 of SEQ ID NO:1.

Example 10

A DNA sequence containing nucleotides 466 to 615 of SEQ ID NO:1 encoding the amino acids 156 to 205 of CD83 was used as input data in the MFOLD program to calculate the secondary structure of the corresponding RNA molecule. A folding temperature of 37°C was used. The most probable secondary structure based on this calculation, i.e. the secondary structure having the most negative energy in kcal/mol is presented in Figure 16 (-29.7 kcal/mol) and the second most probable in Figure 17 (-28.4 kcal/mol).

Each of these secondary structures has a domain (stem-loop-2) comprising a single 3-pronged stem-loop structure and containing the CD83 RNA sub-fragment from nucleotide 466 to nucleotide 615 of SEQ ID NO:1.

Example 11

Specific protein-RNA interactions were detected by Surface Plasmon Resonance using the BIAcore X optical biosensor (Pharmacia Biosensor AB, Upsala, Sweden).

The RNA used contained nucleotides 466 to 615 of SEQ ID NO:1 having a molecular mass of 48,350 gr/mol.

The GST-fusion proteins of interest (GST alone or GST-ELAV (HuR)) were immobilized onto the surface of a CM5 Chip (Pharmacia Biosensor AB, Upsala, Sweden) by using the BIAcore GST Capture Kit (Pharmacia Biosensor AB, Upsala, Sweden), according to the manufacturers instructions, until a change of at least 1,000 resonance units (RU) was detectable.

1 µg of in vitro transcribed RNA (using the T7/SP6 Riboprobe Kit, Promega, Mannheim, Germany) was diluted in a total

volume of 80 μ l HBS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) polysorbate 20) and was allowed to flow over the chip at a flow rate of 50 μ l/minute. The standard running buffer was HBS-EP buffer. The sensor surface was regenerated between assays by injecting 30 μ l of 0.5 M NaCl to remove bound analyte.

Determination of K_D values and calculation of binding specificity were performed using BIAEvaluation Software 3.1 (Pharmacia Biosensor AB, Upsala, Sweden).

The K_D value of the binding of HuR to a portion of the CD83 from nucleotides 466 to 615 of SEQ ID NO:1 was determined to be $7.0-8.0 \times 10^{-6}$ M. Thus, it could be shown that binding of HuR to this portion of the CD83 mRNA occurs with high affinity and is highly specific.

SEQUENCE LISTING

<110> Viacxcel Biotech GmbH

<120> Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds .

<130> 84201

<140>

<141>

<160> 27

<170> PatentIn Ver. 2.1

<210> 1

<211> 613

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(615)

<400> 1

atg tgg cgc gcc ctc cag ctt ctg ctc ctg agc tgc gcc tac agc ctg 43

Met Ser Arg Gly Leu Gln Leu Leu Leu Leu Ser Cys Ala Tyr Ser Leu

1

5

10

15

gct ccc gcc acg ccg gag gtg aag gtg gct tgc tcc gaa gat gtg gac 96

Ala Pro Ala Thr Pro Glu Val Lys Val Ala Cys Ser Glu Asp Val Asp

20

25

30

tgg ccc tgc acc gcc ccc tgg gat ccg cag gct ccc tac acg gtc tcc 144

Leu Pro Cys Thr Ala Pro Trp Asp Pro Gln Val Pro Tyr Thr Val Ser

35	40	45	
tgq gtc aag cta ttg gag ggt ggt gaa gag agg atg gag aca ccc cag	192		
Trp Val Lys Leu Leu Glu Gly Gly Glu Glu Arg Met Glu Thr Pro Gln			
50	55	60	
gaa gac cac ctc agg gga cag cac tat cat cag aag ggg caa aat ggt	240		
Glu Asp His Leu Arg Gly Gln His Tyr His Gln Lys Gly Gln Asn Gly			
65	70	75	80
tct ttc gac gcc ccc aat gaa agg ccc tat tcc ctg aag atc cga aac	288		
Ser Phe Asp Ala Pro Asn Glu Arg Pro Tyr Ser Leu Lys Ile Arg Asn			
85	90	95	
act acc agc tgc aac tcg ggg aca tac agg tgc act ctg cag gac ccg	336		
Thr Thr Ser Cys Asn Ser Gly Thr Tyr Arg Cys Thr Leu Gln Asp Pro			
100	105	110	
gat ggg cag aga aac cta agt gcc aag gtg atc ttg aga gtg aca gga	384		
Asp Gly Gln Arg Asn Leu Ser Gly Lys Val Ile Leu Arg Val Thr Gly			
115	120	125	
tgc cct gca cag cgt aaa gaa gag act ttt aag aaa tac aga gcg gag	432		
Cys Pro Ala Gln Arg Lys Glu Glu Thr Phe Lys Lys Tyr Arg Ala Glu			
130	135	140	
att gtc ctg ctg ctg gct ctg gtt att ttc tac tta aca ctc atc att	480		
Ile Val Leu Leu Leu Ala Leu Val Ile Phe Tyr Leu Thr Leu Ile Ile			
145	150	155	160
ttc act tgt aag ttt gca cgg cta cag agt atc ttc cca gat ttt tct	528		
Phe Thr Cys Lys Phe Ala Arg Leu Gln Ser Ile Phe Pro Asp Phe Ser			
165	170	175	
aaa gct ggc atg gaa cga gct ttt ctc cca gtt acc tcc cca aat aag	576		
Lys Ala Gly Met Glu Arg Ala Phe Leu Pro Val Thr Ser Pro Asn Lys			
180	185	190	

cat tta ggg cta gtg acc ccc cac aag aca gaa ccg gta tja 615
His Leu Gly Leu Val Thr Pro His Lys Thr Glu Leu Val

195

200

205

<210> 2

<211> 205

<212> PRT

<213> Homo sapiens

<400> 2

Met Ser Arg Gly Leu Gln Leu Leu Leu Leu Ser Cys Ala Tyr Ser Leu

1

5

10

15

Ala Pro Ala Thr Pro Glu Val Lys Val Ala Cys Ser Glu Asp Val Asp

20

25

30

Leu Pro Cys Thr Ala Pro Trp Asp Pro Gln Val Pro Tyr Thr Val Ser

35

40

45

Trp Val Lys Leu Leu Glu Gly Gly Glu Glu Arg Met Glu Thr Pro Gln

50

55

60

Glu Asp His Leu Arg Gly Gln His Tyr His Gln Lys Gly Gln Asn Gly

65

70

75

80

Ser Phe Asp Ala Pro Asn Glu Arg Pro Tyr Ser Leu Lys Ile Arg Asn

85

90

95

Thr Thr Ser Cys Asn Ser Gly Thr Tyr Arg Cys Thr Leu Gln Asp Pro

100

105

110

Asp Gly Gln Arg Asn Leu Ser Gly Lys Val Ile Leu Arg Val Thr Gly

115

120

125

Cys Pro Ala Gln Arg Lys Glu Glu Thr Phe Lys Lys Tyr Arg Ala Glu

130 135 140
 Ile Val Leu Leu Leu Ala Leu Val Ile Phe Tyr Leu Thr Leu Ile Ile
 145 150 155 160
 Phe Thr Cys Lys Phe Ala Arg Leu Gln Ser Ile Phe Pro Asp Phe Ser
 165 170 175
 Lys Ala Gly Met Glu Arg Ala Phe Leu Pro Val Thr Ser Pro Asn Lys
 180 185 190
 His Leu Gly Leu Val Thr Pro His Lys Thr Glu Leu Val
 195 200 205

<210> 3

<211> 2051

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (14)..(601)

<400> 3

gagctccagc cgc atg tcg caa gcc ctc cag ctc ctg ttt cta gcc tgc 49

Met Ser Gln Gly Leu Gln Leu Leu Phe Leu Gly Cys

1

5

10

gcc tgc agc ctg gca ccc gag atg gag atg cgg gag gtg acc gtg gct 97

Ala Cys Ser Leu Ala Pro Ala Met Ala Met Arg Glu Val Thr Val Ala

15

20

25

tgc tcc gag acc gcc gac ttg cct tgc aca gcc ccc tgg gac ccg cag 145

Cys Ser Glu Thr Ala Asp Leu Pro Cys Thr Ala Pro Trp Asp Pro Gln

30

35

40

ctc tcc tat gca gtg tcc tgg gcc aag gtc tcc gag agt ggc acc gag	193
Leu Ser Tyr Ala Val Ser Trp Ala Lys Val Ser Glu Ser Gly Thr Glu	
45 50 55 60	
agt gtg gag ctc ccg gag agc aag caa aac agc tcc ttc gag gcc ccc	241
Ser Val Glu Leu Pro Glu Ser Lys Gln Asn Ser Ser Phe Glu Ala Pro	
65 70 75	
agg aga agg gcc tat tcc ctg acg atc caa aac act acc atc tgc agc	289
Arg Arg Arg Ala Tyr Ser Leu Thr Ile Gln Asn Thr Thr Ile Cys Ser	
80 85 90	
tcg ggc acc tac agg tgt gcc ctg cag gag ctc gga ggg cag cgc aac	337
Ser Gly Thr Tyr Arg Cys Ala Leu Gln Glu Leu Gly Gly Gln Arg Asn	
95 100 105	
ttg agc ggc acc gtg gtt ctg aag gtg aca gga tgc ccc aag gaa gct	385
Leu Ser Gly Thr Val Val Leu Lys Val Thr Gly Cys Pro Lys Glu Ala	
110 115 120	
aca gag tca act ttc agg aag tac agg gca gaa gct gtg ttg ctc ttc	433
Thr Glu Ser Thr Phe Arg Lys Tyr Arg Ala Glu Ala Val Leu Leu Phe	
125 130 135 140	
tct ctg gtt gtt ttc tac ctg aca ctc atc att ttc acc tgc aaa ttt	481
Ser Leu Val Val Phe Tyr Leu Thr Leu Ile Ile Phe Thr Cys Lys Phe	
145 150 155	
gca cga cta caa agc att ttc cca gat att tct aaa cct ggt acg gaa	529
Ala Arg Leu Gln Ser Ile Phe Pro Asp Ile Ser Lys Pro Gly Thr Glu	
160 165 170	
caa gct ttt ttt cca gtc acc tcc cca agc aaa cat ttg ggg cca gtg	577
Gln Ala Phe Leu Pro Val Thr Ser Pro Ser Lys His Leu Gly Pro Val	
175 180 185	

acc ctt cct aag aca gaa acg gta tgagtaggat ctccactggt tttacaaaag 631

Thr Leu Pro Lys Thr Glu Thr Val

190

195

ccaagggcac atcagatcag tgtgctgaa tgccaccggg acaagagaag aatgagctcc 691

atcctcagat ggcaaccttt ctttgaagtc cttcacctga cagtgggctc cacactactc 751

cctgacacag ggtcttgagc accatcatat gatcacgaag catggagtat caccgcttct 811

ctgtggctgt cagcttaatg tttcatgtgg ctatctggtc aacctcgtga gtgcttttca 871

gtcatctaca agctatgggt agatgcaggt gaagcagggc catgggaaat ttgaacactc 931

tgagctggcc ctgtgacaga ctctgagga cagctgtcct ctctacatc tgggatacat 991

ctctttgaat ttgtcctgtt tcgttgcaac agcccagatg tctcacatct ggccgaaatt 1051

gacaggccaa gctgtgagcc agtgggaaat atttagcaaa taatttccca gtgcgaaggt 1111

cctgctatta gtaaggagta ttatgtgtac atagaaatga gaggtcagtg aactattccc 1171

cagcagggcc ttttcatctg gaaaagacat ccacaaaagc agcaatacag agggatgcc 1231

catttatctt tttaatcttc atgtacttgt caaagaagaa ttttcatgt tttttcaaag 1291

aagtgtgttt ctttcctttt ttaaaatatg aaggtctagt tacatagcat tgctagctga 1351

caagcagcct gagagaagat ggagaatgtt cctcaaaata gggacagcaa gctagaagca 1411

ctgtacagtg ccttgctggg aagggcagac aatggactga gaaaccagaa gtctggccac 1471

aagattgtct gtatgattct ggacgagtc cctgtggctt tcaactctctg gttagttaac 1531

cagatagctt agtctgggtt gaatacaatg gatgtgaagt tgcttgggga aagctgaatg 1591

tagtgaatac attggcaact ctactgggtt gttacattgt tgatatccta gattctctgga 1681
 gctgagcgaa tgcctgtcat atctcagctt gcccatcaat ccaaacacag gaggtacaa 1711
 aaaggacatg agcatggctt ttctgttgaa ctcctcctga gaaacgtgga gactggctca 1741
 gcgctttgcg ctggaaggac taatcacaag ttcttgaaag tatggacctt ggggagctat 1831
 tgcgccarga caggaggaag ttctcagatg ttgcattgat gtaacattgt tgcatttctt 1891
 taatgagctg ggctccttcc tcatttgctt cccaaagaga tttgtccca ctaatggtgt 1951
 gcccatcacc cacactatga aagtaaaagg gatgctgagc agatacagcg tgccttacctc 2011
 tcagccatga ctttcatgct attaaaagaa tgcattgtgaa 2051

<210> 4

<211> 196

<212> PRT

<213> Mus musculus

<400> 4

Met Ser Gln Gly Leu Gln Leu Leu Phe Leu Gly Cys Ala Cys Ser Leu

1 5 10 15

Ala Pro Ala Met Ala Met Arg Glu Val Thr Val Ala Cys Ser Glu Thr

20 25 30

Ala Asp Leu Pro Cys Thr Ala Pro Trp Asp Pro Gln Leu Ser Tyr Ala

35 40 45

Val Ser Trp Ala Lys Val Ser Gln Ser Gly Thr Glu Ser Val Glu Leu

50 55 60

Pro Glu Ser Lys Gln Asn Ser Ser Phe Glu Ala Pro Arg Arg Arg Ala

65 70 75 80

Tyr Ser Leu Thr Ile Gln Asn Thr Thr Ile Cys Ser Ser Gly Thr Tyr
 85 90 95

Arg Cys Ala Leu Gln Glu Leu Gly Gly Gln Arg Asn Leu Ser Gly Thr
 100 105 110

Val Val Leu Lys Val Thr Gly Cys Pro Lys Glu Ala Thr Glu Ser Thr
 115 120 125

Phe Arg Lys Tyr Arg Ala Glu Ala Val Leu Leu Phe Ser Leu Val Val
 130 135 140

Phe Tyr Leu Thr Leu Ile Ile Phe Thr Cys Lys Phe Ala Arg Leu Gln
 145 150 155 160

Ser Ile Phe Pro Asp Ile Ser Lys Pro Gly Thr Glu Gln Ala Phe Leu
 165 170 175

Pro Val Thr Ser Pro Ser Lys His Leu Gly Pro Val Thr Leu Pro Lys
 180 185 190

Thr Glu Thr Val
 195

<210> 5

<211> 961

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(978)

<407> 5

atg tct aat ggt tat gaa gac cac atg gcc gaa gac tgc agg ggt gac 43
Met Ser Asn Gly Tyr Glu Asp His Met Ala Glu Asp Cys Arg Gly Asp
1 5 10 15

atc ggg aga acg aat ttg atc gtc aac tac ctc cct cag aac atg acc 86
Ile Gly Arg Thr Asn Leu Ile Val Asn Tyr Leu Pro Gln Asn Met Thr
20 25 30

cag gat gag tta cga agc ctg ttc agc agc att ggt gaa gtt gaa tct 144
Gln Asp Glu Leu Arg Ser Leu Phe Ser Ser Ile Gly Glu Val Glu Ser
35 40 45

gca aaa ctt att cgg gat aaa gta gca gga cac agc ttg ggc tac ggc 192
Ala Lys Leu Ile Arg Asp Lys Val Ala Gly His Ser Leu Gly Tyr Gly
50 55 60

ttt gtg aac tac gtg acc gcg aag gat gca gag aga gcg atc aac acg 240
Phe Val Asn Tyr Val Thr Ala Lys Asp Ala Glu Arg Ala Ile Asn Thr
65 70 75 80

ctg aac ggc ttg agg ctc cag tca aaa acc att aag gtg tcg tat gct 298
Leu Asn Gly Leu Arg Leu Gln Ser Lys Thr Ile Lys Val Ser Tyr Ala
85 90 95

cgc ccg agc tca gag gtg atc aaa gac gcc aac ttg tac atc agc ggg 356
Arg Pro Ser Ser Glu Val Ile Lys Asp Ala Asn Leu Tyr Ile Ser Gly
100 105 110

ctc ccg cgg acc atg acc cag aag gac gta gaa gac atg ttc tct cgg 394
Leu Pro Arg Thr Met Thr Gln Lys Asp Val Glu Asp Met Phe Ser Arg
115 120 125

ttt ggg cgg atc atc aac tcg cgg gtc ctc gtg gat cag act aca ggt 452
Phe Gly Arg Ile Ile Asn Ser Arg Val Leu Val Asp Gln Thr Thr Gly
130 135 140

tgg tcc aga ggg ggt ggg ttt acc cgg ttc gac aaa cgg tcg gag gca 481

Leu Ser Arg Gly Val Ala Phe Ile Arg Phe Asp Lys Arg Ser Glu Ala
 145 150 155 160

gaa gag gca att acc agt ttc aat ggt cat aaa ccc cca ggt tcc tct 528
 Glu Glu Ala Ile Thr Ser Phe Asn Gly His Lys Pro Pro Gly Ser Ser
 165 170 175

gag ccc atc gca gtg aag ttt gca gcc aac ccc aac cag aac aaa aac 576
 Glu Pro Ile Ala Val Lys Phe Ala Ala Asn Pro Asn Gln Asn Lys Asn
 180 185 190

gtg gca ctc ctc tcg cag ctg tac cac tcg cca gcg cga cgg ttc gga 624
 Val Ala Leu Leu Ser Gln Leu Tyr His Ser Pro Ala Arg Arg Phe Gly
 195 200 205

ggc ccc gtt cac cac cag gcg cag aga ttc agg ttc tcc ccc atg ggc 672
 Gly Pro Val His His Gln Ala Gln Arg Phe Arg Phe Ser Pro Met Gly
 210 215 220

gtc gat cac atg agc ggg ctc tct ggc gtc aac gtg cca gga aac gcc 720
 Val Asp His Met Ser Gly Leu Ser Gly Val Asn Val Pro Gly Asn Ala
 225 230 235 240

tcc tcc ggc tgg tgc att ttc atc tac aac ctg ggg cag gat gcc gac 768
 Ser Ser Gly Trp Cys Ile Phe Ile Tyr Asn Leu Gly Gln Asp Ala Asp
 245 250 255

gag ggg atc ctc tgg cag atg ttt ggg ccg ttt ggt gcc gtc acc aac 816
 Glu Gly Ile Leu Trp Gln Met Phe Gly Pro Phe Gly Ala Val Thr Asn
 260 265 270

gtg aaa gtg att cgc gac ttc aac acc aac aag tgc aaa ggg ttt ggc 864
 Val Lys Val Ile Arg Asp Phe Asn Thr Asn Lys Cys Lys Gly Phe Gly
 275 280 285

ttt gtg acc atg aca aac tac gaa gaa gcc gcg atg gcc ata gcc agc 912
 Phe Val Thr Met Thr Asn Tyr Glu Glu Ala Ala Met Ala Ile Ala Ser

290

295

300

ctg aac ggc tac cgc ctg ggg gac aaa atc tta cag gtt tcc ttc aaa 960

Leu Asn Gly Tyr Arg Leu Gly Asp Lys Ile Leu Gln Val Ser Phe Lys

305

310

315

320

acc aac aag tcc cac aaa taa

961

Thr Asn Lys Ser His Lys

325

<210> 6

<211> 326

<212> PRT

<213> Homo sapiens

<400> 6

Met Ser Asn Gly Tyr Glu Asp His Met Ala Glu Asp Cys Arg Gly Asp

1

5

10

15

Ile Gly Arg Thr Asn Leu Ile Val Asn Tyr Leu Pro Gln Asn Met Thr

20

25

30

Gln Asp Glu Leu Arg Ser Leu Phe Ser Ser Ile Gly Glu Val Glu Ser

35

40

45

Ala Lys Leu Ile Arg Asp Lys Val Ala Gly His Ser Leu Gly Tyr Gly

50

55

60

Phe Val Asn Tyr Val Thr Ala Lys Asp Ala Glu Arg Ala Ile Asn Thr

65

70

75

80

Leu Asn Gly Leu Arg Leu Gln Ser Lys Thr Ile Lys Val Ser Tyr Ala

85

90

95

Arg Pro Ser Ser Glu Val Ile Lys Asp Ala Asn Leu Tyr Ile Ser Gly

100

105

110

Leu Pro Arg Thr Met Thr Gln Lys Asp Val Glu Asp Met Phe Ser Arg
 115 120 125

Phe Gly Arg Ile Ile Asn Ser Arg Val Leu Val Asp Gln Thr Thr Gly
 130 135 140

Leu Ser Arg Gly Val Ala Phe Ile Arg Phe Asp Lys Arg Ser Glu Ala
 145 150 155 160

Glu Glu Ala Ile Thr Ser Phe Asn Gly His Lys Pro Pro Gly Ser Ser
 165 170 175

Glu Pro Ile Ala Val Lys Phe Ala Ala Asn Pro Asn Gln Asn Lys Asn
 180 185 190

Val Ala Leu Leu Ser Gln Leu Tyr His Ser Pro Ala Arg Arg Phe Gly
 195 200 205

Gly Pro Val His His Gln Ala Gln Arg Phe Arg Phe Ser Pro Met Gly
 210 215 220

Val Asp His Met Ser Gly Leu Ser Gly Val Asn Val Pro Gly Asn Ala
 225 230 235 240

Ser Ser Gly Trp Cys Ile Phe Ile Tyr Asn Leu Gly Gln Asp Ala Asp
 245 250 255

Glu Gly Ile Leu Trp Gln Met Phe Gly Phe Phe Gly Ala Val Thr Asn
 260 265 270

Val Lys Val Ile Arg Asp Phe Asn Thr Asn Lys Cys Lys Gly Phe Gly
 275 280 285

Phe Val Thr Met Thr Asn Tyr Glu Glu Ala Ala Met Ala Ile Ala Ser
 290 295 300

Leu Asn Gly Tyr Arg Leu Gly Asp Lys Ile Leu Gln Val Ser Phe Lys
 305 310 315 320

Thr Asn Lys Ser His Lys
 325

<210> 7

<211> 36

<212> DNA

<213> Homo sapiens

<400> 7

atttaaaagc ttatgtcgcg cggcctccag cttctg 36

<210> 8

<211> 42

<212> DNA

<213> Homo sapiens

<400> 8

atttaagaat tctcaggtag tctttcggat cttcaggga ta 42

<210> 9

<211> 42

<212> DNA

<213> Homo sapiens

<400> 9

atttaaaagc ttatgtctcag gggacagcac taccattaga ag 42

<210> 10

<211> 44

<212> DNA

<213> Homo sapiens

<400> 10

atttaagaat tctcaaaaag tctcttcttt acgctgtgca gggc

44

<210> 11

<211> 39

<212> DNA

<213> Homo sapiens

<400> 11

attcaaaagc ttatgagctg caactggggg acatacagg

39

<210> 12

<211> 42

<212> DNA

<213> Homo sapiens

<400> 12

atttaagaat tctcatacca gttctgtctt gtgaggagtc ac

42

<210> 13

<211> 43

<212> DNA

<213> Homo sapiens

<400> 13

atttaagaat tctcagtaga aaataaccag agccagcagc agg

43

<210> 14

<211> 47

<212> DNA

<213> Homo sapiens

<400> 14

attctaaagc ttatgttaac attcatcatt ttacattgta agtttgc

47

<210> 15

<211> 42

<212> DNA

<213> Homo sapiens

<400> 15

atttaaggat cttttaagaa atacagagcg gagattgtcc tg

42

<210> 16

<211> 42

<212> DNA

<213> Homo sapiens

<400> 16

atttaabccg ggtaccagtc ctgtcttgcg aggagtcact ag

42

<210> 17

<211> 42

<212> DNA

<213> Homo sapiens

<400> 17

atttaabccg ggtttaagaa atacagagcg gagattgtcc tg

42

<210> 18

<211> 42

<212> DNA

<213> Homo sapiens

<400> 18

atttaaggat cctaccagtt ctgtcttggtc aggagtcact ag

42

<210> 19

<211> 60

<212> DNA

<213> Homo sapiens

<400> 19

gattcttttaa gaaatacaga gcggagattg tcctgctgct ggctctggtt atttctacc 60

<210> 20

<211> 52

<212> DNA

<213> Homo sapiens

<400> 20

gaaattcttt atgtctcgcc tctaacagga cgacgaccga gaccaataaa ag

52

<210> 21

<211> 44

<212> DNA

<213> Homo sapiens

<400> 21

atttaaggat ccttaacact catcatcttc acttgtaagt ttgc

44

<210> 22

<211> 1077

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1'..(1077)

<400> 22

atg gaa aca caa ctg tct aat ggg cca act tgc aat aac aca gcc aat 48
Met Glu Thr Gln Leu Ser Asn Gly Pro Thr Cys Asn Asn Thr Ala Asn

1 5 10 15

ggc cca acc acc ata aac aac aac tgt tgc tca cca gtt gac tct ggg 96
Gly Pro Thr Thr Ile Asn Asn Asn Cys Ser Ser Pro Val Asp Ser Gly

20 25 30

aac aca gaa gac agc aag acc aac tta ata gtc aac tac ctt cct cag 144
Asn Thr Glu Asp Ser Lys Thr Asn Leu Ile Val Asn Tyr Leu Pro Gln

35 40 45

aac atg aca cag gag gaa cta aag agt ctc ttt ggg agc att ggt gaa 192
Asn Met Thr Gln Glu Glu Leu Lys Ser Leu Phe Gly Ser Ile Gly Glu

50 55 60

ata gag tcc tgt aag ctt gta aga gac aaa ata aca ggg cag agc ttg 240
Ile Glu Ser Cys Lys Leu Val Arg Asp Lys Ile Thr Gly Gln Ser Leu

65 70 75 80

gga tat ggc tct gtg aac tac att gac ccc aag gat gca gag aaa gct 288
Gly Tyr Gly Phe Val Asn Tyr Ile Asp Pro Lys Asp Ala Glu Lys Ala

85 90 95

atc aac acc ctg aat gga ttg aga ctt caa acc aaa aca ata aaa gct 336
Ile Asn Thr Leu Asn Gly Leu Arg Leu Gln Thr Lys Thr Ile Lys Val

100 105 110

tcc tat ggt cgc cca agt tca gct tct atc aga gat gca aat tta tat 384
Ser Tyr Ala Arg Pro Ser Ser Ala Ser Ile Arg Asp Ala Asn Leu Tyr

115 120 125

gtc agc gga ctt cca aaa aca atg acc cag aag gag ttg yaa cag ctt 431
 Val Ser Gly Leu Pro Lys Thr Met Thr Gln Lys Glu Leu Glu Gln Leu
 130 135 140

ttt tca caa tat gga cgc att att act tct cgt att ctt gtc gac cag 433
 Phe Ser Gln Tyr Gly Arg Ile Ile Thr Ser Arg Ile Leu Val Asp Gln
 145 150 155 160

gtc act ggc ata tca agg ggt gta ggg ttt att cga ttt gac aag cga 523
 Val Thr Gly Ile Ser Arg Gly Val Gly Phe Ile Arg Phe Asp Lys Arg
 165 170 175

att gag gca gaa gaa gct atc aaa ggc cta aat ggc cag aaa cct ccc 576
 Ile Glu Ala Glu Glu Ala Ile Lys Gly Leu Asn Gly Gln Lys Pro Pro
 180 185 190

ggc gcc acg gag cca atc act gta aag ttt gct aat aac cca agc caa 624
 Gly Ala Thr Glu Pro Ile Thr Val Lys Phe Ala Asn Asn Pro Ser Gln
 195 200 205

aaa acc aat cag gcc atc ctt tcc cag ctg tac cag tct cca aac aga 672
 Lys Thr Asn Gln Ala Ile Leu Ser Gln Leu Tyr Gln Ser Pro Asn Arg
 210 215 220

agg tat cca gga ccg cta gct cag cag gca cag cgt ttt agg ttg gac 720
 Arg Tyr Pro Gly Pro Leu Ala Gln Gln Ala Gln Arg Phe Arg Leu Asp
 225 230 235 240

aat ctg ctc aat atg gct tat gga gta aag agg ttt tct cca acg acc 769
 Asn Leu Leu Asn Met Ala Tyr Gly Val Lys Arg Phe Ser Pro Met Thr
 245 250 255

att gag gga atg acc agt ttg gct gga att aat atc cct ggg cac cct 816
 Ile Asp Gly Met Thr Ser Leu Ala Gly Ile Asn Ile Pro Gly His Pro
 260 265 270

gga aca ggg tgg tga ata ttt ggg tac aac ctg gct cct gac gca gat 884
 Gly Thr Gly Trp Cys Ile Phe Val Tyr Asn Leu Ala Pro Asp Ala Asp
 275 280 285

gag agt atc ctg tgg caa atg ttt ggg cct ttt gga gct gtc acc aat 912
 Glu Ser Ile Leu Trp Gln Met Phe Gly Pro Phe Gly Ala Val Thr Asn
 290 295 300

gtg aag gtc atc cgt gac ttt aac acc aat aaa tgc aaa ggt ttt gga 960
 Val Lys Val Ile Arg Asp Phe Asn Thr Asn Lys Cys Lys Gly Phe Gly
 305 310 315 320

ttt gtg act atg aca aac tat gat gag gct gcc atg gcg ata cgt agc 1008
 Phe Val Thr Met Thr Asn Tyr Asp Glu Ala Ala Met Ala Ile Arg Ser
 325 330 335

ctc aat gga tac cgt ctg gga gac aga gta ctg cag gtc tcc ttt aag 1056
 Leu Asn Gly Tyr Arg Leu Gly Asp Arg Val Leu Gln Val Ser Phe Lys
 340 345 350

aca aac aaa atg cac aaa gcc 1077
 Thr Asn Lys Thr His Lys Ala
 355

<210> 23

<211> 359

<212> PRT

<213> Homo sapiens

<400> 23

Met Glu Thr Gln Leu Ser Asn Gly Pro Thr Cys Asn Asn Thr Ala Asn
 1 5 10 15

Gly Pro Thr Thr Ile Asn Asn Asn Cys Ser Ser Pro Val Asp Ser Gly
 20 25 30

Asn Thr Glu Asp Ser Lys Thr Asn Leu Ile Val Asn Tyr Leu Pro Gln
 35 40 45

Asn Met Thr Gln Glu Glu Leu Lys Ser Leu Phe Gly Ser Ile Gly Glu
 50 55 60

Ile Glu Ser Cys Lys Leu Val Arg Asp Lys Ile Thr Gly Gln Ser Leu
 65 70 75 80

Gly Tyr Gly Phe Val Asn Tyr Ile Asp Pro Lys Asp Ala Glu Lys Ala
 85 90 95

Ile Asn Thr Leu Asn Gly Leu Arg Leu Gln Thr Lys Thr Ile Lys Val
 100 105 110

Ser Tyr Ala Arg Pro Ser Ser Ala Ser Ile Arg Asp Ala Asn Leu Tyr
 115 120 125

Val Ser Gly Leu Pro Lys Thr Met Thr Gln Lys Glu Leu Glu Gln Leu
 130 135 140

Phe Ser Gln Tyr Gly Arg Ile Ile Thr Ser Arg Ile Leu Val Asp Gln
 145 150 155 160

Val Thr Gly Ile Ser Arg Gly Val Gly Phe Ile Arg Phe Asp Lys Arg
 165 170 175

Ile Glu Ala Glu Glu Ala Ile Lys Gly Leu Asn Gly Gln Lys Pro Pro
 180 185 190

Gly Ala Thr Glu Pro Ile Thr Val Lys Phe Ala Asn Asn Pro Ser Gln
 195 200 205

Lys Thr Asn Gln Ala Ile Leu Ser Gln Leu Tyr Gln Ser Pro Asn Arg
 210 215 220

Arg Tyr Pro Gly Pro Leu Ala Gln Gln Ala Gln Arg Phe Arg Leu Asp

225 230 235 240

Asn Leu Leu Asn Met Ala Tyr Gly Val Lys Arg Phe Ser Pro Met Thr

245 250 255

Ile Asp Gly Met Thr Ser Leu Ala Gly Ile Asn Ile Pro Gly His Pro

260 265 270

Gly Thr Gly Trp Cys Ile Phe Val Tyr Asn Leu Ala Pro Asp Ala Asp

275 280 285

Glu Ser Ile Leu Trp Gln Met Phe Gly Pro Phe Gly Ala Val Thr Asn

290 295 300

Val Lys Val Ile Arg Asp Phe Asn Thr Asn Lys Cys Lys Gly Phe Gly

305 310 315 320

Phe Val Thr Met Thr Asn Tyr Asp Glu Ala Ala Met Ala Ile Arg Ser

325 330 335

Leu Asn Gly Tyr Arg Leu Gly Asp Arg Val Leu Gln Val Ser Phe Lys

340 345 350

Thr Asn Lys Thr His Lys Ala

355

<210> C4

<211> 1077

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> 1 ..1177.

<400> 24

atg gtc acc cag ata ctg ggg gcc atg gag tct cag gtg ggg ggg gcc 48
 Met Val Thr Gln Ile Leu Gly Ala Met Glu Ser Gln Val Gly Gly Gly

1 5 10 15

ccg gcc ggc ccg gcc ctg ccc aac ggg cca ctc ctt ggt aca aat gga 96
 Pro Ala Gly Pro Ala Leu Pro Asn Gly Pro Leu Leu Gly Thr Asn Gly

20 25 30

gcc act gac gac agc aag acc aac ctc atc gtc aac tac ctg ccc cag 144
 Ala Thr Asp Asp Ser Lys Thr Asn Leu Ile Val Asn Tyr Leu Pro Gln

35 40 45

aac atg acc cag gat gag ttc aag agt ctc ttc ggc agc att ggc gac 192
 Asn Met Thr Gln Asp Glu Phe Lys Ser Leu Phe Gly Ser Ile Gly Asp

50 55 60

atc gag tcc tgc aag ttg gtt cgg gac aag atc aca ggc aga gac ctt 240
 Ile Glu Ser Cys Lys Leu Val Arg Asp Lys Ile Thr Gly Arg Asp Leu

65 70 75 80

ggc tac ggg ttt gtg aac tat cct gac ccc aat gat gca gac aaa gcc 288
 Gly Tyr Gly Phe Val Asn Tyr Pro Asp Pro Asn Asp Ala Asp Lys Ala

85 90 95

atc aac acc ctc aac ggc ctc aaa tta cag acg aag acc atc aag gtg 336
 Ile Asn Thr Leu Asn Gly Leu Lys Leu Gln Thr Lys Thr Ile Lys Val

100 105 110

tcc tat gcc aga ccc agt tca gca tcc atc cgg gat gct aac ctg tac 384
 Ser Tyr Ala Arg Pro Ser Ser Ala Ser Ile Arg Asp Ala Asn Leu Tyr

115 120 125

gtc agc ggg ctc ccc aag acc atg agc cag aaa gag atg gag cag ctc 432
 Val Ser Gly Leu Pro Lys Thr Met Ser Gln Lys Glu Met Glu Gln Leu

130 135 140

ttc tcc cag tac ggc cgc atc atc aag tcc cgc atc ctg gtg gac cag 460
 Phe Ser Gln Tyr Gly Arg Ile Ile Thr Ser Arg Ile Leu Val Asp Gln
 145 150 155 160

gtc aca ggt gtc tcc cgg ggt gtg gga ttc atc cgc ttt gac aag agg 528
 Val Thr Gly Val Ser Arg Gly Val Gly Phe Ile Arg Phe Asp Lys Arg
 165 170 175

att gag gcc gaa gag gct atc aaa gga ctg aat ggg cag aag ccg ctg 576
 Ile Glu Ala Glu Glu Ala Ile Lys Gly Leu Asn Gly Gln Lys Pro Leu
 180 185 190

ggc gca gct gag ccc atc aca gtc aag ttc gcg aac aac cca agt cag 624
 Gly Ala Ala Glu Pro Ile Thr Val Lys Phe Ala Asn Asn Pro Ser Gln
 195 200 205

aag acg ggg cag gcg ctg ctc acc cac ctc tac cag tca tcc gcc cgg 672
 Lys Thr Gly Gln Ala Leu Leu Thr His Leu Tyr Gln Ser Ser Ala Arg
 210 215 220

cgc tac gca ggc ccc cta cac cat cag acc cag cgt ttc cgg ctg gac 720
 Arg Tyr Ala Gly Pro Leu His His Gln Thr Gln Arg Phe Arg Leu Asp
 225 230 235 240

aat ttg ctc aac atg gcc tac ggc gtc aag agg ttc tcg ccg atc gcc 768
 Asn Leu Leu Asn Met Ala Tyr Gly Val Lys Arg Phe Ser Pro Ile Ala
 245 250 255

atc gat ggt atg agg ggc ctg gcg ggc ctg ggc ctg tcg ggg ggc gcg 816
 Ile Asp Gly Met Ser Gly Leu Ala Gly Val Gly Leu Ser Gly Gly Ala
 260 265 270

ggg ggc ggc tgg tgc atc ttc gtg tac aac ctg tca ccg gag gca gac 864
 Ala Gly Gly Trp Cys Ile Phe Val Tyr Asn Leu Ser Pro Glu Ala Asp
 275 280 285

gag agc gtg ctg cgg cag ctg tcc ggg cct ttt ggg gca gtc acc aac 912

Glu Ser Val Leu Trp Gln Leu Phe Gly Pro Phe Gly Ala Val Thr Asn
 290 295 300

gtc aag gtc atc cgt gat ttc acc acc aac aag tgc aag ggt ttc ggc 960
 Val Lys Val Ile Arg Asp Phe Thr Thr Asn Lys Cys Lys Gly Phe Gly
 305 310 315 320

ttc gtg acc atg acc aac tat gac gag gcg gcc atg gcc atc gcc agc 1008
 Phe Val Thr Met Thr Asn Tyr Asp Glu Ala Ala Met Ala Ile Ala Ser
 325 330 335

ctg aac ggc tat cgc ctg gcc gag cgc gtg ctg cag gtc tcc ttc aag 1056
 Leu Asn Gly Tyr Arg Leu Ala Glu Arg Val Leu Gln Val Ser Phe Lys
 340 345 350

acc agc aaa cag cac aag gcg 1077
 Thr Ser Lys Gln His Lys Ala
 355

<210> 25

<211> 359

<212> PRT

<213> Homo sapiens

<400> 25

Met Val Thr Gln Ile Leu Gly Ala Met Glu Ser Gln Val Gly Gly Gly
 1 5 10 15

Pro Ala Gly Pro Ala Leu Pro Asn Gly Pro Leu Leu Gly Thr Asn Gly
 20 25 30

Ala Thr Asp Asp Ser Lys Thr Asn Leu Ile Val Asn Tyr Leu Pro Gln
 35 40 45

Asn Met Thr Gln Asp Glu Phe Lys Ser Leu Phe Gly Ser Ile Gly Asp
 50 55 60

Ile Glu Ser Cys Lys Leu Val Arg Asp Lys Ile Thr Gly Arg Asp Leu
65 70 75 80

Gly Tyr Gly Phe Val Asn Tyr Pro Asp Pro Asn Asp Ala Asp Lys Ala
85 90 95

Ile Asn Thr Leu Asn Gly Leu Lys Leu Gln Thr Lys Thr Ile Lys Val
100 105 110

Ser Tyr Ala Arg Pro Ser Ser Ala Ser Ile Arg Asp Ala Asn Leu Tyr
115 120 125

Val Ser Gly Leu Pro Lys Thr Met Ser Gln Lys Glu Met Glu Gln Leu
130 135 140

Phe Ser Gln Tyr Gly Arg Ile Ile Thr Ser Arg Ile Leu Val Asp Gln
145 150 155 160

Val Thr Gly Val Ser Arg Gly Val Gly Phe Ile Arg Phe Asp Lys Arg
165 170 175

Ile Glu Ala Glu Glu Ala Ile Lys Gly Leu Asn Gly Gln Lys Pro Leu
180 185 190

Gly Ala Ala Glu Pro Ile Thr Val Lys Phe Ala Asn Asn Pro Ser Gln
195 200 205

Lys Thr Gly Gln Ala Leu Leu Thr His Leu Tyr Gln Ser Ser Ala Arg
210 215 220

Arg Tyr Ala Gly Pro Leu His His Gln Thr Gln Arg Phe Arg Leu Asp
225 230 235 240

Asn Leu Leu Asn Met Ala Tyr Gly Val Lys Arg Phe Ser Pro Ile Ala
245 250 255

Ile Asp Gly Met Ser Gly Leu Ala Gly Val Gly Leu Ser Gly Gly Ala
 260 265 270

Ala Gly Gly Trp Cys Ile Phe Val Tyr Asn Leu Ser Pro Glu Ala Asp
 275 280 285

Glu Ser Val Leu Trp Gln Leu Phe Gly Pro Phe Gly Ala Val Thr Asn
 290 295 300

Val Lys Val Ile Arg Asp Phe Thr Thr Asn Lys Cys Lys Gly Phe Gly
 305 310 315 320

Phe Val Thr Met Thr Asn Tyr Asp Glu Ala Ala Met Ala Ile Ala Ser
 325 330 335

Leu Asn Gly Tyr Arg Leu Ala Glu Arg Val Leu Gln Val Ser Phe Lys
 340 345 350

Thr Ser Lys Gln His Lys Ala
 355

<210> 26

<211> 1140

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1140)

<400> 26

atg gtt atg ara att agc acc atg gag cct cag gtg tca aat ggt cgg 48

Met Val Met Ile Ile Ser Thr Met Glu Pro Gln Val Ser Asn Gly Pro

1

5

10

15

aca tcc aat acg agc aat gga ccc tcc agc aac aac aga aac tgt cct	96
Thr Ser Asn Thr Ser Asn Gly Pro Ser Ser Asn Asn Arg Asn Cys Pro	
20 25 30	
tct cct atg caa acg ggg gca acc acg gat gac agc aaa acc aac ctc	144
Ser Pro Met Gln Thr Gly Ala Thr Thr Asp Asp Ser Lys Thr Asn Leu	
35 40 45	
atc gtc aac tat tta ccc cag aat atg acc caa gaa gaa ttc agg agt	192
Ile Val Asn Tyr Leu Pro Gln Asn Met Thr Gln Glu Glu Phe Arg Ser	
50 55 60	
ctc ttc ggg agc att ggt gaa ata gaa tcc tgc aaa ctt gtg aga gac	240
Leu Phe Gly Ser Ile Gly Glu Ile Glu Ser Cys Lys Leu Val Arg Asp	
65 70 75 80	
aaa att acg gga cag agt tta ggg tat gga ttt gtt aac tat att gat	288
Lys Ile Thr Gly Gln Ser Leu Gly Tyr Gly Phe Val Asn Tyr Ile Asp	
85 90 95	
cca aag gat gca gag aaa gcc atc aac act tta aat gga ctc aga ctc	336
Pro Lys Asp Ala Glu Lys Ala Ile Asn Thr Leu Asn Gly Leu Arg Leu	
100 105 110	
cag acc aaa acc ata aag gtc tca tat gcc cgt ccg agc tct gcc tca	384
Gln Thr Lys Thr Ile Lys Val Ser Tyr Ala Arg Pro Ser Ser Ala Ser	
115 120 125	
atc agg gat gct aac ctc tat gtt agc ggc ctt ccc aaa acc atg acc	432
Ile Arg Asp Ala Asn Leu Tyr Val Ser Gly Leu Pro Lys Thr Met Thr	
130 135 140	
cag aag gaa ctg gag caa ctt ttc tgg caa tac ggc cgt atc atc acc	480
Gln Lys Glu Leu Glu Gln Leu Phe Ser Gln Tyr Gly Arg Ile Ile Thr	
145 150 155 160	
tca cga atc ctg gct gat caa gtc acg gga gtc tcc aga ggg gtc gga	528

Ser Arg Ile Leu Val Asp Gln Val Thr Gly Val Ser Arg Gly Val Gly
 165 170 175

ttc atc cgc ttt gat aag agg att gag gca gaa gaa gcc atc aaa ggg 576
 Phe Ile Arg Phe Asp Lys Arg Ile Glu Ala Glu Glu Ala Ile Lys Gly
 180 185 190

ctg aat ggc cag aag ccc agc ggt gct acg gaa ccg att act gtg aag 624
 Leu Asn Gly Gln Lys Pro Ser Gly Ala Thr Glu Pro Ile Thr Val Lys
 195 200 205

ttt gcc aac aac ccc agc cag aag tcc agc cag gcc ctg ctc tcc cag 672
 Phe Ala Asn Asn Pro Ser Gln Lys Ser Ser Gln Ala Leu Leu Ser Gln
 210 215 220

ctc tac cag tcc cct aac cgg cgc tac cca ggt cca ctt cac cac cag 720
 Leu Tyr Gln Ser Pro Asn Arg Arg Tyr Pro Gly Pro Leu His His Gln
 225 230 235 240

gct cag agg ttc agg ctg gac aat ttg ctt aat atg gcc tat ggc gta 768
 Ala Gln Arg Phe Arg Leu Asp Asn Leu Leu Asn Met Ala Tyr Gly Val
 245 250 255

aag aga ctg atg tct gga cca gtc ccc cct tct gct tgt tcc ccc agg 816
 Lys Arg Leu Met Ser Gly Pro Val Pro Pro Ser Ala Cys Ser Pro Arg
 260 265 270

ttc tcc cca att acc att gat gga atg aca agc ctt gtg gga atg aac 864
 Phe Ser Pro Ile Thr Ile Asp Gly Met Thr Ser Leu Val Gly Met Asn
 275 280 285

atc cct ggt cac aca gga act ggg tgg tgc atc ttt gtc tac aac ctg 912
 Ile Pro Gly His Thr Gly Thr Gly Trp Cys Ile Phe Val Tyr Asn Leu
 290 295 300

tcc ccc gat tcc gat gag agt gtc ctc tgg cag ctc ttt ggc ccc ttt 960
 Ser Pro Asp Ser Asp Glu Ser Val Leu Trp Gln Leu Phe Gly Pro Phe

Caa gtt tcc ttt aaa atc aac aaa gcc cac aag tcc 1140
 Gln Val Ser Phe Lys Thr Asn Lys Ala His Lys Ser
 370 375 380

<213> Homo sapiens

10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200
 50 50 60

Leu Phe Gly Ser Ile Gly Glu Ile Glu Ser Cys Lys Leu Val Arg Asp
65 70 75 80

Lys Ile Thr Gly Gln Ser Leu Gly Tyr Gly Phe Val Asn Tyr Ile Asp
85 90 95

Pro Lys Asp Ala Glu Lys Ala Ile Asn Thr Leu Asn Gly Leu Arg Leu
100 105 110

Gln Thr Lys Thr Ile Lys Val Ser Tyr Ala Arg Pro Ser Ser Ala Ser
115 120 125

Ile Arg Asp Ala Asn Leu Tyr Val Ser Gly Leu Pro Lys Thr Met Thr
130 135 140

Gln Lys Glu Leu Glu Gln Leu Phe Ser Gln Tyr Gly Arg Ile Ile Thr
145 150 155 160

Ser Arg Ile Leu Val Asp Gln Val Thr Gly Val Ser Arg Gly Val Gly
165 170 175

Phe Ile Arg Phe Asp Lys Arg Ile Glu Ala Glu Glu Ala Ile Lys Gly
180 185 190

Leu Asn Gly Gln Lys Pro Ser Gly Ala Thr Glu Pro Ile Thr Val Lys
195 200 205

Phe Ala Asn Asn Pro Ser Gln Lys Ser Ser Gln Ala Leu Leu Ser Gln
210 215 220

Leu Tyr Gln Ser Pro Asn Arg Arg Tyr Pro Gly Pro Leu His His Gln
225 230 235 240

Ala Gln Arg Phe Arg Leu Asp Asn Leu Leu Asn Met Ala Tyr Gly Val
245 250 255

Lys Arg Leu Met Ser Gly Pro Val Pro Pro Ser Ala Cys Ser Pro Arg

260	265	270
Phe Ser Pro Ile Thr Ile Asp Gly Met Thr Ser Leu Val Gly Met Asn		
275	280	285
Ile Pro Gly His Thr Gly Thr Gly Trp Cys Ile Phe Val Tyr Asn Leu		
290	295	300
Ser Pro Asp Ser Asp Glu Ser Val Leu Trp Gln Leu Phe Gly Pro Phe		
305	310	315
		320
Gly Ala Val Asn Asn Val Lys Val Ile Arg Asp Phe Asn Thr Asn Lys		
325	330	335
Cys Lys Gly Phe Gly Phe Val Thr Met Thr Asn Tyr Asp Glu Ala Ala		
340	345	350
Met Ala Ile Ala Ser Leu Asn Gly Tyr Arg Leu Gly Asp Arg Val Leu		
355	360	365
Gln Val Ser Phe Lys Thr Asn Lys Ala His Lys Ser		
370	375	380

Claims

1. A compound that specifically blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduces expression of a member of the CD83 family of proteins in a cell.
2. A compound according to claim 1, characterized in that said compound comprises a nucleic acid.
3. A compound according to claim 1 or 2, characterized in that the compound comprises DNA.
4. A compound according to claim 1 or 2, characterized in that the compound comprises RNA.
5. A compound according to any of the preceding claims, characterized in that the compound contains at least a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof.
6. A compound according to any of the preceding claims, characterized in that the compound contains from nucleotide 466 to 618 of the sequence in SEQ ID NO:1 or a derivative thereof.
7. A compound according to any of the preceding claims, characterized in that the compound contains from nucleotide 466 to 615 of the sequence in SEQ ID NO:1 or a derivative thereof.
8. A compound according to any of the preceding claims, characterized in that the compound contains a nucleic acid having a secondary structure comprising a 3-pronged

stem-loop structure with an energy of -28.4 kcal/mol or less, preferably -29.7 kcal/mol or less.

9. A compound according to any of the preceding claims, characterized in that the compound is a nucleic acid that comprises regulatory sequences that lead to the transcription of an RNA molecule from said nucleic acid in a cell.
10. A compound according to any of the preceding claims, characterized in that the compound is a nucleic acid that does not contain regulatory sequences that lead to the translation of a polypeptide or protein from said nucleic acid in a cell.
11. A compound according to claim 1, characterized in that said compound comprises a protein.
12. A compound according to claim 11, characterized in that said protein is a derivative of members of the ELAV superfamily of proteins.
13. A compound according to claim 12, characterized in that said protein is selected from the group of proteins consisting of ELAV, HuR, HuB, HuC, HuD, HuDpro, HuDmex, Hel-N2 and HuC isoforms, Rel-N1 and naturally occurring homologues of these proteins.
14. A compound according to claim 11, characterized in that said protein is a derivative of a protein ligand to HuR.
15. A compound according to claim 14, characterized in that said protein is selected from the group of proteins consisting of SET α , SET β , pp32 and APRIL as well as naturally occurring homologues of these proteins.

16. A pharmaceutical composition comprising a compound according to any of claims 1 to 15.
17. The use of a compound according to any of claims 1 to 15 for the production of a pharmaceutical composition for treating or preventing disease involving the direct or indirect participation of DC.
18. The use according to claim 17, characterized in that said disease is selected from the group consisting of diseases involving the growth, differentiation and/or activation of cytotoxic T cells and helper T cells, the differentiation of helper T cells into Th1 cells or Th2 cells, the growth, stimulation and/or differentiation of B cells.
19. The use according to claim 17, characterized in that said disease is selected from the group consisting of allergies, asthma autoimmune syndromes such as myasthenia gravis, multiple sclerosis and systemic lupus erythematosus, skin diseases such as psoriasis, rheumatoid arthritis and AIDS.
20. The use of a compound a compound according to any of claims 1 to 15 for the production of a pharmaceutical composition for treating or preventing rejection of a tissue or organ transplant.
21. An expression vector comprising a nucleic acid sequence encoding a ribonucleic acid according to any of claims 4 to 10.
22. A host cell transformed with the expression vector according to claim 21.
23. The use of an expression vector encoding an ribonucleic acid according to any of claims 4 to 10 for the

production of a medicament for the treatment and prevention of disorders, diseases and syndromes involving the direct or indirect participation of DC by regulating an immune response.


24. An expression vector comprising a nucleic acid sequence encoding a protein according to any of claims 11 to 15.
25. A host cell transformed with the expression vector according to claim 24.
26. The use of an expression vector encoding a protein according to any of claims 11 to 15 for the production of a medicament for the treatment and prevention of disorders, diseases and syndromes involving the direct or indirect participation of DC by regulating an immune response.
27. Method for screening and/or identifying compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins comprising the steps of incubating one or more compounds in a reaction comprising:
 - (a) a nucleic acid molecule that contains at least a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof and
 - (b) a member of the ELAV superfamily of proteins or derivative thereofunder conditions sufficient to allow the components to interact and determining whether the compound blocks the binding between the nucleic acid molecule and the member of the ELAV superfamily of proteins.
28. Method according to claim 27, characterized in that the member of the CD83 family of proteins is CD83.

29. Method according to claim 27 or 28, characterized in that the member of the ELAV superfamily of proteins is selected from the group consisting of ELAV, HuR, HuB, HuC, HuD, HuDpro, HuDmex, Hel-N2 and HuC isoforms, Rel-N1 and naturally occurring homologues of these proteins.
30. Method according to any of claims 27 to 29, characterized in that said method is carried out in the form of an assay selected from the group RNA gel shift assay, filter binding assay, Biacore interaction analysis, Scintillation Proximity Assay, RNase protection assay, cell-based RNA binding assay, yeast 3-hybrid assays and reporter gene assay.
31. Use of a compound that blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins when incubated in a reaction comprising:
 - (a) a nucleic acid molecule that contains at least a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof and
 - (b) a member of the ELAV superfamily of proteins or derivative thereofunder conditions sufficient to allow the components to interact, for the production of a pharmaceutical composition for treating or preventing disease involving the direct or indirect participation of DC.

Abstract


The present invention relates to compounds that specifically block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell as well as pharmaceutical compositions comprising such compounds and methods for screening and/or identifying compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins.

Figure 1



This Page Blank (uspto)

Figure 2




This Page Blank (uspto)

Figure 3



Figure 4



This Page Blank (uspto)

Figure 5






Figure 6




This Page Blank (uspto)

Figure 7




This Page Blank (uspto)

Figure 8



This Page Blank (uspto)

Figure 9



This Page Blank (uspto)


Figure 10




This Page Blank (uspto)

Figure 11

starting vector no. 1 : pBC12/HIV/CAT




starting vector no. 2 : pBC12/CMV/ β - Gal/SD-SA :




endonuclease cleavage with *Bam HI* and *Xma I*
and ligation of the corresponding
PCR product of CD83

CD83



This Page Blank (uspto)


Figure 12



Transient Transfection of COS Cells


This Page Blank (uspto)

Figure 13



This Page Blank (uspto)


Figure 14



Transient Transfection of COS Cells

This Page Blank (uspto)


Figure 15



Transient Transfection of COS Cells


This Page Blank (uspto)

Figure 16



This Page Blank (uspto)

Figure 17



This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☒ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)